[
    {
        "chunk_id": "rr6210_chunk_0",
        "document_id": "rr6210",
        "text": "Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html. \nRecommendations and Reports / Vol. 62 / No. 10\t\nDecember 20, 2013 \nU.S. Department of Health and Human Services\nCenters for Disease Control and Prevention\nMorbidity and Mortality Weekly Report\nCDC Guidance for Evaluating Health-Care Personnel \nfor Hepatitis B Virus Protection and for \nAdministering Postexposure Management\nRecommendations and Reports\nThe MMWR series of publications is published by the Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention (CDC), \nU.S. Department of Health and Human Services, Atlanta, GA 30333.\nSuggested Citation: Centers for Disease Control and Prevention. [Title]. MMWR 2013;62(No. RR-#):[inclusive page numbers].",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_1",
        "document_id": "rr6210",
        "text": "Centers for Disease Control and Prevention\nThomas R. Frieden, MD, MPH, Director \nHarold W. Jaffe, MD, MA, Associate Director for Science \nJoanne Cono, MD, ScM, Acting Director, Office of Science Quality \nChesley L. Richards, MD, MPH, Deputy Director for Public Health Scientific Services\nMMWR Editorial and Production Staff\nRonald L. Moolenaar, MD, MPH, Editor, MMWR Series\nChristine G. Casey, MD, Deputy Editor, MMWR Series\nTeresa F. Rutledge, Managing Editor, MMWR Series\nDavid C. Johnson, Lead Technical Writer-Editor\nDenise Williams, MBA, Project Editor\nMartha F. Boyd, Lead Visual Information Specialist\nMaureen A. Leahy, Julia C. Martinroe, \nStephen R. Spriggs, Terraye M. Starr\nVisual Information Specialists\nQuang M. Doan, MBA, Phyllis H. King\nInformation Technology Specialists",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_2",
        "document_id": "rr6210",
        "text": "Quang M. Doan, MBA, Phyllis H. King\nInformation Technology Specialists\nMMWR Editorial Board\nWilliam L. Roper, MD, MPH, Chapel Hill, NC, Chairman\nMatthew L. Boulton, MD, MPH, Ann Arbor, MI\nVirginia A. Caine, MD, Indianapolis, IN\nBarbara A. Ellis, PhD, MS, Atlanta, GA\nJonathan E. Fielding, MD, MPH, MBA, Los Angeles, CA\nDavid W. Fleming, MD, Seattle, WA\nWilliam E. Halperin, MD, DrPH, MPH, Newark, NJ\nKing K. Holmes, MD, PhD, Seattle, WA\nTimothy F. Jones, MD, Nashville, TN\nRima F. Khabbaz, MD, Atlanta, GA\nDennis G. Maki, MD, Madison, WI\nPatricia Quinlisk, MD, MPH, Des Moines, IA\nPatrick L. Remington, MD, MPH, Madison, WI\nWilliam Schaffner, MD, Nashville, TN\nCONTENTS\nIntroduction.............................................................................................................1",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_3",
        "document_id": "rr6210",
        "text": "Methods....................................................................................................................3\nRecommendations............................................................................................. 11\nFuture Studies...................................................................................................... 16\nDisclosure of Relationship\nCDC, our planners, content experts and their spouses/partners \nwish to disclose that they have no financial interests or other \nrelationships with the manufacturers of commercial products, \nsuppliers of commercial services, or commercial supporters. Planners \nhave reviewed content to ensure there is no bias.  \nRecommendations and Reports\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\t\n1",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_4",
        "document_id": "rr6210",
        "text": "Recommendations and Reports\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\t\n1\nCDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus \nProtection and for Administering Postexposure Management\nSarah Schillie, MD1\nTrudy V. Murphy, MD1\nMark Sawyer, MD2\nKathleen Ly, MPH1\nElizabeth Hughes, DrPH1\nRuth Jiles, PhD1\nMarie A. de Perio, MD3\nMeredith Reilly, MPH4\nKathy Byrd, MD1\nJohn W. Ward, MD1\n1National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC\n2University of California at San Diego\n3National Institute for Occupational Safety and Health, CDC\n4Johns Hopkins University, School of Public Health\nSummary\nThis report contains CDC guidance that augments the 2011 recommendations of the Advisory Committee on Immunization",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_5",
        "document_id": "rr6210",
        "text": "Practices (ACIP) for evaluating hepatitis B protection among health-care personnel (HCP) and administering post-exposure \nprophylaxis. Explicit guidance is provided for persons working, training, or volunteering in health-care settings who have documented \nhepatitis B (HepB) vaccination years before hire or matriculation (e.g., when HepB vaccination was received as part of routine \ninfant [recommended since 1991] or catch-up adolescent [recommended since 1995] vaccination).\nIn the United States, 2,890 cases of acute hepatitis B were reported to CDC in 2011, and an estimated 18,800 new cases of hepatitis B \noccurred after accounting for underreporting of cases and asymptomatic infection. Although the rate of acute hepatitis B virus (HBV)",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_6",
        "document_id": "rr6210",
        "text": "infections have declined approximately 89% during 1990\u20132011, from 8.5 to 0.9 cases per 100,000 population in the United States, \nthe risk for occupationally acquired HBV among HCP persists, largely from exposures to patients with chronic HBV infection.\nACIP recommends HepB vaccination for unvaccinated or incompletely vaccinated HCP with reasonably anticipated risk for blood \nor body fluid exposure. ACIP also recommends that vaccinated HCP receive postvaccination serologic testing (antibody to hepatitis B \nsurface antigen [anti-HBs]) 1\u20132 months after the final dose of vaccine is administered (CDC. Immunization of health-care personnel: \nrecommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2011;60 [No. RR-7]). Increasing",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_7",
        "document_id": "rr6210",
        "text": "numbers of HCP have received routine HepB vaccination either as infants (recommended since 1991) or as catch-up vaccination \n(recommended since 1995) in adolescence. HepB vaccination results in protective anti-HBs responses among approximately 95% \nof healthy-term infants. Certain institutions test vaccinated HCP by measuring anti-HBs upon hire or matriculation, even when \nanti-HBs testing occurs greater than 2 months after vaccination. This guidance can assist clinicians, occupational health and \nstudent health providers, infection-control specialists, hospital and health-care training program administrators, and others in \nselection of an approach for assessing HBV protection for vaccinated HCP. This report emphasizes the importance of administering",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_8",
        "document_id": "rr6210",
        "text": "HepB vaccination for all HCP, provides explicit guidance for evaluating hepatitis B protection among previously vaccinated HCP \n(particularly those who were vaccinated in infancy or adolescence), and clarifies recommendations for postexposure management \nof HCP exposed to blood or body fluids.\nIntroduction\nHepatitis B virus (HBV) has long been recognized as an \noccupational risk for health-care personnel (HCP), including \nHCP trainees (1,2). The virus remains infectious for prolonged \nperiods on environmental surfaces and is transmissible in \nthe absence of visible blood (1). HCP do not recognize all \nexposures to potentially infectious blood or body fluids (2) and, \neven if exposures are recognized, often do not seek postexposure",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_9",
        "document_id": "rr6210",
        "text": "even if exposures are recognized, often do not seek postexposure \nprophylactic management (3). In serologic studies conducted \nin the United States during the 1970s, HCP had a prevalence \nof HBV infection approximately 10 times greater than the \ngeneral population (1). In 1983, an estimated 17,000 HBV \ninfections occurred among HCP (4).\nVaccines to prevent HBV became available in the United States \nin 1981 and were recommended by the Advisory Committee \nCorresponding preparer: Sarah Schillie, MD, Division of Viral \nHepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, \nand TB Prevention, CDC. Telephone: 404-718-8608; E-mail: \nsschillie@cdc.gov.\nRecommendations and Reports\n2\t\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\non Immunization Practices (ACIP) for HCP in 1982 (5).",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_10",
        "document_id": "rr6210",
        "text": "on Immunization Practices (ACIP) for HCP in 1982 (5). \nAlthough a high proportion of healthy vaccine recipients in \nclinical trials respond to hepatitis B (HepB) vaccination, the \nproportion of responders can be lower among the general \npopulation, particularly among persons with chronic medical \nconditions (6,7). Acute and chronic HBV infections are rare \namong HCP who respond to HepB vaccination, but HCP who \ndo not respond to vaccination are thought to remain susceptible. \nPostvaccination serologic testing for antibody to hepatitis B \nsurface antigen (anti-HBs) identifies vaccine nonresponders \nand guides the need for revaccination, additional testing for \nchronic HBV infection, and counseling for HCP who remain \nsusceptible after failing to respond to vaccination.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_11",
        "document_id": "rr6210",
        "text": "susceptible after failing to respond to vaccination.\nIn 1991, ACIP recommended consideration of \npostvaccination serologic testing for anti-HBs for HCP at risk \nfor needlestick exposures (8). In 1997, ACIP recommended \npostvaccination serologic testing 1\u20132 months after completion \nof the HepB vaccine series for HCP who have contact with \npatients or blood and who are at ongoing risk for injuries with \nsharp instruments or needlesticks (9). Since 1982 (when HepB \nvaccine was recommended for HCP), major declines have \noccurred in reports of acute hepatitis B among HCP (10). In \n2011, ACIP reaffirmed that unvaccinated and incompletely \nvaccinated HCP at reasonably anticipated risk for blood or \nbody fluid exposure should receive HepB vaccination before",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_12",
        "document_id": "rr6210",
        "text": "body fluid exposure should receive HepB vaccination before \npotential exposure, and HCP at high risk for exposure should \nreceive postvaccination serologic testing 1\u20132 months after \ncompletion of the vaccine series (11).\nThis report provides CDC guidance for persons working, \ntraining, or volunteering in health-care settings who have \ndocumented HepB vaccination received years before hire or \nmatriculation (e.g., when HepB vaccination was received as \npart of routine infant [recommended since 1991] or catch-up \nadolescent [recommended since 1995] vaccination). No \npostvaccination serologic testing is recommended after routine \ninfant or adolescent HepB vaccination. Although acute HBV \ninfections have declined substantially since HepB vaccination was",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_13",
        "document_id": "rr6210",
        "text": "infections have declined substantially since HepB vaccination was \nintroduced in the United States, a risk for occupational exposure \nto HBV persists (10), largely from persons with chronic HBV \ninfection. Because vaccine-induced anti-HBs wanes over time, \ntesting HCP for anti-HBs years after vaccination might not \ndistinguish vaccine nonresponders from responders. Pre-exposure \nassessment of current or past anti-HBs results upon hire or \nmatriculation, followed by one or more additional doses of HepB \nvaccine for HCP with anti-HBs <10 mIU/mL, if necessary, helps \nto ensure that HCP will be protected if they have an exposure to \nHBV-containing blood or body fluids.\nAn expert panel convened by CDC acknowledged that the \nrisk for HBV infection for vaccinated HCP can vary widely",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_14",
        "document_id": "rr6210",
        "text": "risk for HBV infection for vaccinated HCP can vary widely \nby setting and profession, and might be low enough in certain \nsettings that assessment of anti-HBs status and appropriate \nfollow-up can be done at the time of exposure to potentially \ninfectious blood or body fluids. This approach relies on HCP \nrecognizing and reporting blood and body fluid exposures \nand therefore might be applied on the basis of documented \nlow risk, implementation, and cost considerations. Certain \nHCP occupations have lower risk for occupational blood \nand body fluid exposures (e.g., occupations involving \ncounseling versus performing procedures), and nontrainees \nhave lower risks for blood and body fluid exposures than \ntrainees. Some settings also will have a lower prevalence of",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_15",
        "document_id": "rr6210",
        "text": "trainees. Some settings also will have a lower prevalence of \nHBV infection in the patient population served than in other \nsettings, which will influence the risk for HCP exposure to \nhepatitis B surface antigen (HBsAg)-positive blood and body \nfluids. All health-care institutions should ensure that HCP \nreceive training to recognize and report exposures, have systems \nin place to facilitate reporting and postexposure assessment, and \nhave prophylaxis readily accessible for timely administration. \nThis report can guide clinicians, occupational health and \nstudent health clinicians, infection-control specialists, hospital \nand health-care training program administrators, and others \nin selection of an approach for assessing HBV protection for \nvaccinated HCP.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_16",
        "document_id": "rr6210",
        "text": "in selection of an approach for assessing HBV protection for \nvaccinated HCP.\nHCPs are defined as all paid and unpaid persons providing \nhealth care, or working or training in health-care settings, who \nhave reasonably anticipated risks for exposure to infectious \nmaterials, including blood or body fluids, contaminated medical \nsupplies and equipment, or contaminated environmental \nsurfaces. HCP might include but are not limited to physicians, \nnurses, nursing assistants, nurse practitioners, physician \nassistants, therapists, technicians, emergency medical services \npersonnel, dental personnel, pharmacists, laboratory personnel, \nautopsy personnel, health-care students and trainees, \ncontractual staff not employed by the health-care facility, and",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_17",
        "document_id": "rr6210",
        "text": "contractual staff not employed by the health-care facility, and \npersons not directly involved in patient care but with potential \nexposure to infectious agents that can be transmitted between \npatients and HCP (e.g., housekeeping, laundry, security, \nmaintenance, and volunteers) (1,11).\nThis guidance applies but is not limited to HCP in acute-care \nhospitals, long-term\u2013care facilities (e.g., nursing homes, skilled \nnursing facilities, and assisted living facilities), physician\u2019s \noffices, dental offices, rehabilitation centers, urgent-care \ncenters, ambulatory surgical centers, dialysis centers, and \noutpatient clinics, and to persons who provide home health \ncare and emergency medical services. Although this guidance \npertains to HCP, the same principles might be applicable to",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_18",
        "document_id": "rr6210",
        "text": "pertains to HCP, the same principles might be applicable to \npersons in other professions with reasonably anticipated risk \nfor blood or body fluid exposure (e.g., public safety workers, \nembalmers, and crime scene cleanup crews).\nRecommendations and Reports\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\t\n3\nRecommendations for testing HCP in certain populations \nat risk for acquisition of HBV infection before matriculation \nor hire can be found elsewhere and will be reviewed only \nbriefly in this document (11\u201313). HCP protection against \nhepatitis C virus (HCV), human immunodeficiency virus \n(HIV), and other infections also is covered elsewhere \n(1,11,14). Postvaccination serologic testing and the need for \nrevaccination specific to HCP with immunocompromising",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_19",
        "document_id": "rr6210",
        "text": "revaccination specific to HCP with immunocompromising \nconditions (e.g., HCP who are on dialysis, infected with HIV, \nhematopoietic stem-cell transplant recipients, and receiving \nchemotherapy) are addressed in separate recommendations \n(15). Additional guidance on the management of HCP with \nchronic HBV infection has been published (13). A list of \nfrequently used abbreviations is provided (Box).\nNew or Updated Information Provided in \nthis Guidance\nThis document examines approaches for assessing HBV \nprotection for vaccinated HCP and offers additional \nguidance for postexposure evaluation and testing of HCP in \nconsideration of:\n\u2022 The changing epidemiology of HBV infections in the \nUnited States\n\u2022 The risk for occupational blood or body fluid exposures",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_20",
        "document_id": "rr6210",
        "text": "United States\n\u2022 The risk for occupational blood or body fluid exposures \nsince introduction of engineering and work-practice \ncontrols and the Needlestick Safety and Prevention Act \nof 2001\n\u2022 HCP reporting of blood or body fluid exposures\n\u2022 HepB vaccination coverage among HCP\n\u2022 Estimates of the proportion of adults with measureable \nanti-HBs at intervals after vaccination\n\u2022 Duration of vaccine-induced protection\n\u2022 Current vaccination and postvaccination serologic testing \npractices\n\u2022 Cost-effectiveness of approaches for assessing HBV \nprotection among HCP, and\n\u2022 Recommendations for administering postexposure \nmanagement.\nMethods\nIn 2012, CDC identified and convened subject matter experts \nin the fields of HBV infection, health-care epidemiology, and",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_21",
        "document_id": "rr6210",
        "text": "in the fields of HBV infection, health-care epidemiology, and \nevidence-based medicine to form an expert panel to address \nmechanisms for assessing HBV protection for vaccinated HCP.* \nThe expert panel was comprised of professionals from academic \nmedicine (e.g., pediatrics, family medicine, internal medicine, \nand infectious diseases) and occupational health; federal and \nstate public health professionals with expertise in hepatitis \nand health-care associated infections; and liaisons from the \nSociety for Healthcare Epidemiology of America (SHEA), \nHealthcare Infection Control Practices Advisory Committee \n(HICPAC), American Medical Directors Association (AMDA), \nAmerican College Health Association (ACHA), American \nAcademy of Family Physicians (AAFP), and the Society",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_22",
        "document_id": "rr6210",
        "text": "Academy of Family Physicians (AAFP), and the Society \nfor Adolescent Health and Medicine (SAHM). The expert \npanel convened 21 teleconferences for deliberations during \nJanuary 19, 2012\u2013January 8, 2013. Materials for teleconference \ndiscussion were electronically distributed to members.\nThe expert panel reviewed relevant published literature \nidentified through PubMed searches, citations, and personal \nfiles. Reference lists were reviewed to retrieve additional \nrelevant information. The expert panel considered the changing \nepidemiology of hepatitis B infections from surveillance reports, \nwhich included follow-up with state health departments to \nobtain additional information on HCP with acute hepatitis B \nduring 2005\u20132010 reported as having a positive or unknown \nBOX. Abbreviations.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_23",
        "document_id": "rr6210",
        "text": "during 2005\u20132010 reported as having a positive or unknown \nBOX. Abbreviations.\nACIP\t\nAdvisory Committee on Immunization \nPractices\nanti-HBc\t\nantibody to hepatitis B core antigen\nanti-HBs\t\nantibody to hepatitis B surface antigen\nELISA\t\nenzyme-linked immunosorbent assay\nHBeAg\t\nhepatitis B e antigen\nHBIG\t\nhepatitis B immune globulin\nHBsAg\t\nhepatitis B surface antigen\nHBV\t\nhepatitis B virus\nHBV DNA\t hepatitis B virus deoxyribonucleic acid\nHCP \t\nhealth-care personnel\nHCV\t\nhepatitis C virus\nHepB\t\nhepatitis B vaccine\nHIV\t\nhuman immunodeficiency virus\nIDU\t\ninjection drug use\nIG\t\nimmune globulin\nIIS\t\nImmunization Information System\nIOM\t\nInstitute of Medicine\nMSM\t\nmen who have sex with men\nNHIS\t\nNational Health Interview Survey\nNNDSS\t\nNational Notifiable Diseases Surveillance \nSystem\nOSHA",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_24",
        "document_id": "rr6210",
        "text": "National Health Interview Survey\nNNDSS\t\nNational Notifiable Diseases Surveillance \nSystem\nOSHA\t\nOccupational Safety and Health \nAdministration\nPCR\t\npolymerase chain reaction\nQALY\t\nquality-adjusted life-year\n*\tA list of the members of the panel appears on page 20.\nRecommendations and Reports\n4\t\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\nHepB vaccination history. The expert panel reviewed previous \nrecommendations from ACIP, HICPAC, and the U.S. Public \nHealth Service; including recommendations defining HCP \nat risk for occupational exposure, HepB vaccination, and \npostvaccination serologic testing. The panel also reviewed \npostexposure prophylaxis (1,5,9,11,13,15,16), and results from \nan electronic survey administered to health-care institutions",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_25",
        "document_id": "rr6210",
        "text": "an electronic survey administered to health-care institutions \nregarding current practices (see Hepatitis B Vaccination and \nPostvaccination Testing among HCP). Various members of the \nexpert panel were consulted to address issues throughout the \ndevelopment of these guidelines. Evidence also was summarized \nin presentations discussed during expert panel teleconferences.\nThe panel identified two approaches for assessing HBV \nprotection for vaccinated HCP, on the basis of expert opinion, \nwhich form the foundation of this guidance. Members of the \nexpert panel critically reviewed earlier drafts of this guidance \ndocument, which was developed by CDC, individually and as \na group by teleconference. Names and affiliations of persons",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_26",
        "document_id": "rr6210",
        "text": "a group by teleconference. Names and affiliations of persons \nwho provided input in the drafting of these recommendations \nare included at the beginning of this document and in the \nacknowledgments section. \nChanging Epidemiology of HBV Infection\nHepatitis B is a nationally reportable disease (17). In the United \nStates, 2,890 cases of acute hepatitis B were reported to CDC in \n2011, and an estimated 18,800 new cases of hepatitis B occurred \nafter accounting for underreporting of cases and asymptomatic \ninfection (Figure 1) (10). Among patients with reported cases \nof acute hepatitis B with information, approximately 55% were \nhospitalized and 1.3% died from hepatitis B (10). Acute HBV \ninfection becomes chronic in 90% of infants, 30% of children",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_27",
        "document_id": "rr6210",
        "text": "infection becomes chronic in 90% of infants, 30% of children \naged <5 years, and <1%\u201312% of adults (18). Approximately 25% \nof persons who become chronically infected during childhood \nand 15% of those who become chronically infected after \nchildhood die prematurely from cirrhosis or liver cancer (1,15). \nAn estimated 800,000\u20131.4 million persons in the United States \nare living with chronic HBV infection; these persons serve as the \nmain reservoir for HBV (12). In contrast to a decline in reports \nof acute hepatitis B, the prevalence of chronic HBV, which is \noften asymptomatic, remained relatively stable (Figure 2) (19) \nat 3 per 100,000 persons (95% confidence interval = 2\u20135 per \n100,000) during 2005\u20132010, as did death certificate-registered \ndeaths (20).",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_28",
        "document_id": "rr6210",
        "text": "100,000) during 2005\u20132010, as did death certificate-registered \ndeaths (20).\nA national strategy to eliminate HBV transmission \nwas implemented in 1991 (16). A key component was a \nrecommendation for routine vaccination of infants (16). As a \nresult, the rate of newly reported acute HBV infections in the \nUnited States declined approximately 89% during 1990\u20132011, \nfrom 8.5 to 0.9 cases per 100,000 population (10,11). The \nincidence was lowest (0.04 cases per 100,000 population) \namong persons aged \u226419 years (10), the population routinely \nvaccinated as infants and adolescents. Although HepB vaccine \ncoverage rates in 2011 were high among infants, children, \nand adolescents (91.1% among children aged 19\u201335 months \nand 92.3% among adolescents aged 13\u201317 years) (21,22),",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_29",
        "document_id": "rr6210",
        "text": "and 92.3% among adolescents aged 13\u201317 years) (21,22), \nself-reported \u22653-dose coverage remained considerably lower \nfor adults (35.9% for adults aged 19\u201349 years in 2011) (23).\nOccupational Risk for HBV Exposure and \nExposure Reporting\nBlood from persons with HBV infection contains the \nhighest HBV titers of all body fluids and is the most important \nvehicle of transmission in the health-care setting (1). The \nfollowing body fluids also are considered potentially infectious: \ncerebrospinal fluid, synovial fluid, pleural fluid, peritoneal \nfluid, pericardial fluid, and amniotic fluid (1). Although studies \nhave documented HBV in saliva and tears, these body fluids \nhave generally not represented an occupational risk for HBV \ninfection unless they contain blood (1). Semen and vaginal",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_30",
        "document_id": "rr6210",
        "text": "infection unless they contain blood (1). Semen and vaginal \nsecretions have been implicated in the sexual transmission \nof HBV, but they have not been implicated in occupational \ntransmission from patients to HCP (1). The presence of HBsAg, \nusually an indicator of active HBV infection, also is found in \nother body fluids (e.g., breast milk, bile, feces, nasopharyngeal \nwashings, and sweat). However, most body fluids are not \nefficient vehicles of transmission (unless they contain blood) \nbecause they contain low quantities of infectious HBV (1). \nSource: CDC. Viral hepatitis statistics and surveillance. Available at http://\nwww.cdc.gov/hepatitis/statistics/index.htm.\n*\tFor 2011, the reported number of cases was 2,890; the estimated number of",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_31",
        "document_id": "rr6210",
        "text": "*\tFor 2011, the reported number of cases was 2,890; the estimated number of \ncases (18,800) was computed after accounting for underreporting and \nasymptomatic infections.\nFIGURE 1. Number* of reported acute hepatitis B cases \u2014 National \nNotifiable Diseases Surveillance System, United States, 2000\u20132011\nT\nhis f\nigur\ne is\n a l\nine \ngrap\nh re\nprese\nnting\n the \nnumbe\nr of \ncases\n repo\nrted \nduring the years 2000 through 2011. For 2011, the reported number of cases is 2,890 and the estimated number of cases (18,800) is after accounting for underreporting and asymptomatic infection.\nRecommendations and Reports\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\t\n5\nSputum, urine, and vomitus are not considered potentially \ninfectious unless they contain blood (1).",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_32",
        "document_id": "rr6210",
        "text": "infectious unless they contain blood (1).\nHBV is highly infectious, can be transmitted in the absence \nof visible blood (1), and remains infectious on environmental \nsurfaces for at least 7 days (24). HBV is transmitted through \npercutaneous (i.e., needlesticks), mucosal (i.e., direct contact \nwith mucous membranes), or nonintact skin (e.g., psoriasis, \neczema, burns, wounds, cuts, and scratches) exposure to \ninfectious blood or body fluids. Although percutaneous \nexposures are among the most efficient modes of HBV \ntransmission, these exposures might account for only a minority \nof HBV infections among HCP. In several investigations of \nHBV outbreaks, most infected HCP could not recall an overt \npercutaneous exposure (2,25).\nHepatitis B e antigen (HBeAg) is a marker for high",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_33",
        "document_id": "rr6210",
        "text": "percutaneous exposure (2,25).\nHepatitis B e antigen (HBeAg) is a marker for high \nHBV replication and viral load (15). Although testing \noccupational exposure source patients for HBeAg is not \npractical and is not recommended, the risk for acquiring \nHBV infection is particularly high in occupational exposures \nto blood or body fluids from source patients who are \nHBeAg-positive (4). In studies of HCP who sustained \ninjuries from needles contaminated with blood containing \nHBV, the risk for developing clinical hepatitis if the \nblood was both HBsAg-positive and HBeAg-positive was \n22%\u201331%; the risk for developing serologic evidence of HBV \ninfection was 37%\u201362% (1,26). By comparison, the risk for \ndeveloping clinical hepatitis from a needle contaminated with",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_34",
        "document_id": "rr6210",
        "text": "developing clinical hepatitis from a needle contaminated with \nHBsAg-positive, HBeAg-negative blood was 1%\u20136%, and the \nrisk for developing serologic evidence of HBV infection was \n23%\u201337% (1,26).\nThe Needlestick Safety and Prevention Act of 2001 directed \nthe Occupational Safety and Health Administration (OSHA) \nto revise the Occupational Exposure to Bloodborne Pathogens \nStandard and established in greater detail requirements for \nemployers regarding the identification and use of effective and \nsafer medical devices (27). Percutaneous injuries have since \ndecreased from 39.6 injuries per 100 occupied beds in 1999 to \n19.5 injuries per 100 occupied beds in 2011 (Figure 3) (28). \nData since 2002 indicate that 18% of HCP trainees sustain",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_35",
        "document_id": "rr6210",
        "text": "Data since 2002 indicate that 18% of HCP trainees sustain \na percutaneous exposure annually, and 54% of percutaneous \nexposures are reported to occupational health (3,29\u201332). \nReluctance to report exposures to occupational health \nmight be influenced by fear of being reprimanded, concerns \nregarding confidentiality, and the belief that reporting might \nbe time consuming (29,31). The annual risk for a mucosal \nexposure among trainees is 22%, of which 17% are reported \nto occupational health (3,29\u201332). The risk for exposure is \ngenerally lower among nontrainees and varies by occupation \nand job duties (32,33). Surveillance data indicate nurses and \nphysicians account for 41.9% and 22.8%, respectively, of HCP \nreporting percutaneous exposures (28). The purpose of the",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_36",
        "document_id": "rr6210",
        "text": "reporting percutaneous exposures (28). The purpose of the \nsharp item that resulted in the exposure was for intramuscular \nor subcutaneous injection in 30.5% of exposures and was for \nsuturing in 18.7% of exposures (28). Medical students account \nfor 44.3% of HCP reporting a mucosal exposure (28).\nThe probability of HBV infection among HCP trainees \nwill vary by the prevalence of HBsAg-positivity of source \npatients and the approach to assessment (Figure 4). Exposure \nlogs during 2000\u20132012 representing 7,170 exposures at three \nhealth-care systems in the United States indicated that 0.9% \nof source patients were HBsAg-positive (34). This figure likely \nvaries substantially by setting; in some community screening \nprograms among populations considered at higher risk,",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_37",
        "document_id": "rr6210",
        "text": "programs among populations considered at higher risk, \n11%\u201325% of persons screened are infected with HBV (35).\nThe source patient is identifiable in approximately 95% of \nexposures (28). The source patient might not be identifiable \nafter exposure from an item protruding from a disposal \ncontainer, an item disposed of in an inappropriate container, \nor from an item left in an inappropriate place (28).\nVaccination\nHepB Vaccines\nHepB vaccine is available as a single-antigen formulation and \nalso in combination with other vaccines (Table 1) (15). Two \nsingle-antigen recombinant HBsAg vaccines are available in the \nUnited States: Recombivax HB (Merck and Co, Inc., \nT\nhis f\nigure i\ns\n a grap\nh that \nreprese\nnts the\n preval\nence \nof ch\nronic\n hepa\ntitis\n B in\nfection, whi",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_38",
        "document_id": "rr6210",
        "text": "igure i\ns\n a grap\nh that \nreprese\nnts the\n preval\nence \nof ch\nronic\n hepa\ntitis\n B in\nfection, whi\nch is defined as the presence of both hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen (anti-Hbc). The period represented is 1976\u20132010.\nSources: Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of \nhepatitis B virus infection in the United States in the era of vaccination. J Infect \nDis 2010;202:192\u2013201. Personal communication. Roberts H, PhD. Atlanta, GA: \nCDC;2012.\n*\tChronic Hepatitis B is defined as the presence of both hepatitis B surface \nantigen (HBsAg) and antibody to hepatitis B core antigen (anti-HBc).\n\u2020\tRepresents 95% confidence interval.\nFIGURE 2. Weighted prevalence of chronic hepatitis B* \u2014 National",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_39",
        "document_id": "rr6210",
        "text": "FIGURE 2. Weighted prevalence of chronic hepatitis B* \u2014 National \nHealth and Nutrition Examination Survey, United States, \n1976\u20132010\nRecommendations and Reports\n6\t\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\nWhitehouse Station, NJ) and Engerix-B (GlaxoSmithKline \nBiologicals, Rixensart, Belgium) (15). Of the three licensed \ncombination vaccines, one (Twinrix [GlaxoSmithKline Biologicals]) \nis available for persons aged \u226518 years. Twinrix contains \nrecombinant HBsAg and inactivated hepatitis A virus (15).\nPrimary HepB vaccination of adults usually consists of 3 doses \nof 10 or 20 \u00b5g of recombinant HBsAg protein administered \nintramuscularly into the deltoid muscle on a 0, 1, and 6 month \nschedule (15). Alternative schedules (including a 4-dose schedule at",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_40",
        "document_id": "rr6210",
        "text": "schedule (15). Alternative schedules (including a 4-dose schedule at \n0, 1, 2, and 12 months) are U.S.-approved for routine vaccination \nfor specific ages and vaccine formulations; vaccination according to \nthese schedules elicits final rates of seroprotection similar to those \nobtained on a 0, 1, and 6 month schedule (15). Obese persons \nmight require adjustment in the needle length for administering \nHepB vaccine to achieve optimal seroprotection (11,15).\nVaccine Safety\nHepB vaccines have been demonstrated to be safe among \npersons in all age groups (15). During 1982\u20132004, an estimated \n70 million adolescents and adults in the United States received \n\u22651 dose of HepB vaccine (15). The most frequently reported side \neffects are pain at the injection site (3%\u201329%) and temperature of",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_41",
        "document_id": "rr6210",
        "text": "effects are pain at the injection site (3%\u201329%) and temperature of \n>99.9\u00b0F (>37.7\u00b0C) (1%\u20136%) (15). In placebo-controlled studies, \nthese side effects were reported no more frequently among persons \nreceiving HepB vaccine than among persons receiving placebo \n(15). Administration of additional vaccine doses for nonresponders \nis not associated with an increase in adverse events (36).\nEpidemiologic and mechanistic assessment by the Institute of \nMedicine for 27 adverse events supported a causal association \nwith HepB vaccination only for anaphylaxis in persons who \nare sensitive to yeast (37). HepB vaccination is contraindicated \nfor persons with a history of hypersensitivity to yeast or any \nvaccine component (15). Persons with a history of serious",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_42",
        "document_id": "rr6210",
        "text": "vaccine component (15). Persons with a history of serious \nadverse events (e.g., anaphylaxis) after receipt of HepB vaccine \nshould not receive additional doses. As with other vaccines, \nvaccination of persons with moderate or severe acute illness, \nwith or without fever, should be deferred until illness resolves \n(15). Vaccination is not contraindicated in persons with \na history of multiple sclerosis, Guillain-Barr\u00e9 Syndrome, \nautoimmune disease (e.g., systemic lupus erythematosis and \nrheumatoid arthritis), or other chronic diseases (15). HepB \nvaccination is not contraindicated for pregnant (15,38,39) or \nlactating (1) women. Available vaccines contain noninfectious \nHBsAg and do not pose a risk for infection to the fetus (15).\nThis\n fig\nure \nis a\n bar\n gra\nph t\nhat \nprov\nides the i",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_43",
        "document_id": "rr6210",
        "text": "This\n fig\nure \nis a\n bar\n gra\nph t\nhat \nprov\nides the i\nncid\nence\n of \ninju\nry b\ny ne\nedle\n \ns\nti\nck\n a\nnd\n m\nuc\nos\nal\n exposure, as repo\nrted by the Exposu\nr\ne\n Prevention and Inf\normation Network during the period 1997\u20132011.\nSource: University of Virginia Health System.  International Healthcare Worker Safety Center. Available at http://www.healthsystem.virginia.edu/pub/epinet/home.html.\n*\tPer 100 occupied beds.\n\u2020\tIncludes needlesticks, cuts, and bites.\n\u00a7\tIncludes contact with mucous membranes or nonintact skin (termed \u201cblood and body fluid exposures\u201d by the Exposure Prevention Information Network [EPINet]).\nFIGURE 3. Incidence* of percutaneous injury\u2020 and mucosal exposure\u00a7 \u2014 Exposure Prevention Information Network, 1997\u20132011\nRecommendations and Reports",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_44",
        "document_id": "rr6210",
        "text": "Recommendations and Reports\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\t\n7\nVaccine Seroprotection\nImmunocompetent adults and children who have vaccine-\ninduced anti-HBs levels of \u226510 mIU/mL 1\u20132 months after \nhaving received a complete, \u22653-dose HepB vaccine series are \nconsidered seroprotected and deemed vaccine responders \n(15). Vaccine efficacy studies have demonstrated protection \nagainst acute and chronic disease in immunocompetent \nvaccine responders (40,41). Vaccine-induced seroprotection \nis a useful surrogate of vaccine efficacy (42). Postvaccination \nseroprotection is achieved in approximately \n95% of healthy infants (43,44), approximately \n92% of HCP aged <40 years, and approximately \n84% of HCP aged \u226540 years (6). Among \ninfants vaccinated at birth, low birthweight is",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_45",
        "document_id": "rr6210",
        "text": "84% of HCP aged \u226540 years (6). Among \ninfants vaccinated at birth, low birthweight is \nassociated with a lower proportion of infants \nachieving seroprotection (45). Among persons \nvaccinated as adults, smoking, obesity, aging, \nchronic medical conditions, male sex, genetic \nfactors, and immune suppression are associated \nwith a decrease in proportions seroprotected \n(6,11,36,46\u201348). Although immunogenicity \nis less among immunocompromised persons, \nthose who achieve and maintain seroprotective \nantibody levels before exposure to HBV have \na high level of protection (15).\nPersistence of Vaccine-Induced \nAntibody\nAnti-HBs levels after vaccination decline \nover time. The persistence of detectable \nanti-HBs levels varies by age at vaccination. \nBy 18 years after vaccination, approximately",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_46",
        "document_id": "rr6210",
        "text": "anti-HBs levels varies by age at vaccination. \nBy 18 years after vaccination, approximately \n16% of persons vaccinated at age <1 year \nhave detectable antibody levels of \u226510 mIU/mL (49\u201354) \n(Figure 5), compared with 74% for those vaccinated at \nage \u22651 year (41,54\u201362). In a study of matriculating health \nscience students, 92.9% of those who had received 3 doses of \nHepB vaccine had anti-HBs \u226510 mIU/mL (58). Median age at \nreceipt of the primary series was 14.5 years (interquartile range: \n11.6\u201320.2 years) and at postvaccination testing was 23.2 years \n(interquartile range: 22.1\u201324.8 years) (58).\nTABLE 1. Recommended dosages of hepatitis B vaccine, by age, immunocompetency, and vaccine type\nCharacteristic\nSingle-antigen vaccine*\nCombination vaccine\nRecombivax HB\nEngerix-B\nTwinrix\u2020\nDosage",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_47",
        "document_id": "rr6210",
        "text": "Characteristic\nSingle-antigen vaccine*\nCombination vaccine\nRecombivax HB\nEngerix-B\nTwinrix\u2020\nDosage\n(\u00b5g)\nVolume\n(mL)\nDosage\n(\u00b5g)\nVolume\n(mL)\nDosage\n(\u00b5g)\nVolume\n(mL)\nAge (yrs)\n11\u201315\n10\u00a7\n1\n NA\nNA\nNA\nNA\n11\u201319\n5\n0.5\n10\n0.5\nNA\nNA\n\u226520 \n10\n1\n20\n1\n20\n1\nHemodialysis patients and other immunocompromised persons\n<20\u00b6\n5\n0.5\n10\n0.5\nNA\nNA\n\u226520\n40**\n1\n40\u2020\u2020\n2\nNA\nNA\nAbbreviation: NA = not applicable. \n\t *\tSingle-antigen vaccine is usually administered on a 3-dose schedule at 0, 1, and 6 months. Other schedules are available. See package insert. \n\t \u2020\tCombined hepatitis A and hepatitis B vaccine is recommended for persons  aged \u226518 years at increased risk for both hepatitis B virus and hepatitis A virus infections. \n\t \u00a7\tAdult formulation administered on a 2-dose schedule.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_48",
        "document_id": "rr6210",
        "text": "\u00a7\tAdult formulation administered on a 2-dose schedule. \n\t \u00b6\tHigher dosages might be more immunogenic, but no specific recommendations have been made. \n\t**\tDialysis formulation administered on a 3-dose schedule at 0, 1, and 6 months. \n\t\u2020\u2020\tTwo 1 mL doses administered at one site on a 4-dose schedule at 0, 1, 2, and 6 months. \nT\nh\nis\n f\nig\nur\ne \nis\n \na li\nne g\nraph\n tha\nt pr\ne\nsents the probability of HBV infection among\n HCP \ntrainees\n on the bas\nis of p\nrevalence of \nHBsAg-positivity of sou\nrce patients and approach to assessment.\nFIGURE 4. Hepatitis B virus infection rate among health-care personnel trainees, by prevalence \nof hepatitis B surface antigen positivity of source patients and approach to assessment",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_49",
        "document_id": "rr6210",
        "text": "of hepatitis B surface antigen positivity of source patients and approach to assessment\nSource: Personal communication. Hoerger TJ, Ludlow-Bradley C. Durham, North Carolina: Research \nTriangle Institute, International; 2012.\n*\tPer 100,000 population of health-care personnel. \nRecommendations and Reports\n8\t\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\nResponse to a Challenge Dose of Vaccine\nTo assess vaccine response in remotely vaccinated HCP, a \nchallenge dose of HepB vaccine can be used to determine \nthe presence of vaccine-induced immunologic memory \nthrough generation of an anamnestic response. The term \n\u201cbooster dose\u201d has been used to refer to a dose of HepB vaccine \nadministered after a primary vaccination series to provide",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_50",
        "document_id": "rr6210",
        "text": "administered after a primary vaccination series to provide \nrapid protective immunity against significant infection (i.e., \ninfection resulting in serologic test results positive for HBV \nand/or clinically significant disease) (40). Among persons \nvaccinated 5.9\u201317.5 years previously at age <1 year who have \nanti-HBs levels <10 mIU/mL, approximately 60.0%\u201397.4% \nshowed a response to a single challenge dose of HepB vaccine \ndemonstrating protective levels of anti-HBs \u226510 mIU/mL \n(50\u201354). Among persons vaccinated 9\u201322 years previously at \nage \u22651 year who have anti-HBs levels <10 mIU/mL, 69.2%\u2013\n96.4% showed a response to a single challenge dose of HepB \nvaccine demonstrating protective levels of anti-HBs \u226510 mIU/\nmL (41,54,60,62). The proportion of responders to a challenge",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_51",
        "document_id": "rr6210",
        "text": "mL (41,54,60,62). The proportion of responders to a challenge \ndose might vary by population and age at receiving the primary \nHepB series. HCP with a response \u226510 mIU/mL following a \nchallenge dose are considered protected, regardless of future \ndeclines in anti-HBs. Conclusions about the response to a \nchallenge dose are made on the basis of relatively few studies \nand might change as additional data become available.\nDuration of Vaccine Protection among \nResponders\nAmong immunocompetent HepB vaccine responders, studies \nsuggest protection against acute symptomatic and chronic \nhepatitis B infection persists for \u226522 years (9,15,40). Three \ncohort studies that monitored 1,006 subjects for \u226520 years \nhave been informative (41,63,64). In two of the cohorts from",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_52",
        "document_id": "rr6210",
        "text": "have been informative (41,63,64). In two of the cohorts from \nareas with high HBV endemicity, new chronic HBV infections \nwere documented in 0.8% (0 and 1.0%) of 513 (109 and 404) \nsubjects, respectively, who responded or presumably responded \nto HepB vaccination starting at birth (63,64). Approximately \n20% of subjects had evidence of natural boosting of anti-HBs, \npresumably from exposure to HBV (63,64). A third cohort \nof 493 subjects in an area with intermediate HBV endemicity \nreceived HepB vaccination between ages 6 months and \n\u226550 years (41). Among vaccine responders, no acute or chronic \nHBV was detected, although 1% of subjects experienced \nsubclinical HBV infection without chronic infection during \n\u226520 years of follow-up (41). The significance of subclinical",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_53",
        "document_id": "rr6210",
        "text": "\u226520 years of follow-up (41). The significance of subclinical \nbreakthrough HBV infection without chronic HBV and \ntransient HBV infection is unknown.\nHepB Vaccination and Postvaccination Testing \namong HCP\nThe Bloodborne Pathogens Standard issued in 1991 by \nOSHA mandates that HepB vaccination be made available \nat the employer\u2019s expense to employees who have reasonably \nanticipated skin, eye, mucous membrane, or parenteral contact \nwith blood or other potentially infectious materials that might \nresult from the performance of an employee\u2019s duties (27). \nHepB vaccination coverage data obtained through the National \nHealth Interview Survey (NHIS) in 2011 demonstrated \n\u22653-dose coverage of 63.8% among HCP aged \u226519 years \n(23). NHIS 2010 data demonstrated \u22653-dose coverage of",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_54",
        "document_id": "rr6210",
        "text": "(23). NHIS 2010 data demonstrated \u22653-dose coverage of \n74% for HCP with direct patient contact, and 46% for HCP \nwithout direct patient contact (65), substantially below the \nHealthy People 2020 target of 90% HepB vaccination coverage \namong HCP (objective no. IID-15.3) (66).\nPostvaccination serologic testing for anti-HBs is recommended \n1\u20132 months after the last vaccine dose for HCP at risk for \noccupational percutaneous or mucosal exposures (11). During \n2012, a survey was administered to 389 California acute care \nhospitals or centers comprised of more than one hospital \nto assess current practices for ensuring HCP protection \nagainst HBV. Hospitals were identified from a listserv of 580 \ninfection prevention and employee health staff (67). Responses",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_55",
        "document_id": "rr6210",
        "text": "infection prevention and employee health staff (67). Responses \nThis figure is a graph that present\ns evidence of protection from h\ne\npa\nti\nti\ns \nB \nvi\nru\ns \non\n th\ne\n \nba\nsi\ns \nof years since vaccination, in 5-year increments, measured by the proportion of persons with anti-HBs  \u226510 mIU/mL.\nSources: Samandari T, Fiore AE, Negus S, et al. Differences in response to a \nhepatitis B vaccine booster dose among Alaskan children and adolescents \nvaccinated during infancy. Pediatrics 2007;120:e373\u201381. Petersen KM, Bulkow LR, \nMcMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving \nhepatitis B vaccinations from birth. Pediatr Infect Dis J 2004;23:650\u20135. \nHammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in children",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_56",
        "document_id": "rr6210",
        "text": "Hammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in children \nvaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up \nstudy at 15 years. Vaccine. 2007;25:6958\u201364. Dentinger CM, McMahon BJ, \nButler JC, et al. Persistence of antibody to hepatitis B and protection from disease \namong Alaska natives immunized at birth. Pediatr Infect Dis J 2005;24:786\u201392. \nMiddleman AB, Baker C, Hu DJ, et al. Duration of immunity from hepatitis B \nvaccine administered soon after birth among 16 to 19 year old youth in the \nUnited States. Presented to the Pediatric Academic Societies, Boston, MA, \nApril 29, 2012.\n*\tIncludes U.S. studies only.\nFIGURE 5. Serologic evidence of protection, by years since vaccination \namong persons vaccinated at age <1 year*",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_57",
        "document_id": "rr6210",
        "text": "among persons vaccinated at age <1 year*\nRecommendations and Reports\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\t\n9\nwere obtained from 153 listserv subscribers, comprising \napproximately 39% of hospitals (67). Responding hospitals \nwere not representative of all hospitals in the United States \n(67). Of the 153 responding hospitals, most (92 [60.1%]) \nwere nongovernment not-for-profit community hospitals, \nfollowed by investor-owned (for-profit) community hospitals \n(32 [20.9%]), and state and local government community \nhospitals (13 [8.5%]) (67). One fourth (37 [24.2%]) were \nteaching hospitals (67). Responding hospitals had between 35 \nand 15,421 (median: 1,000) HCP with reasonably anticipated \nrisk for blood or body fluid exposure (67). The majority",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_58",
        "document_id": "rr6210",
        "text": "risk for blood or body fluid exposure (67). The majority \nof respondents (71.9%) indicated current practices at their \ninstitution consist of measuring anti-HBs on a pre-exposure \nbasis, followed by HepB vaccination if anti-HBs is <10 mIU/mL \n(67). A smaller proportion of respondents (15.7%) indicated \ntheir institution follows an approach relying upon postexposure \nmanagement (67). Postvaccination anti-HBs results were known \nfor approximately 69% of HCP at these facilities (67).\nRevaccination for Vaccine Nonresponse\nRevaccination with \u22651dose of HepB vaccine for nonresponse \nsubsequent to the primary series increases the proportion of \npersons achieving vaccine-induced seroprotection (15). Among \n178 persons with occupational risk for HBV infection, 47%",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_59",
        "document_id": "rr6210",
        "text": "178 persons with occupational risk for HBV infection, 47% \nof those without protective antibody levels after a primary \nvaccination series developed vaccine-induced seroprotection \nafter one additional dose of HepB vaccine (6). An estimated \n42% of 86 persons without protective anti-HBs levels after \nthe first revaccination dose and who received 2 additional \ndoses developed protective levels of anti-HBs representing a \ncumulative response rate of 69% among initial nonresponders \nafter 3 revaccination doses (6). Persons who have measurable \nbut low (i.e., 1\u20139 mIU/mL) levels of anti-HBs after the initial \nseries have better response to revaccination than persons who \nhave no measurable anti-HBs (36,62,68,69).\nSingle dose revaccination with a higher dosage has not been",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_60",
        "document_id": "rr6210",
        "text": "Single dose revaccination with a higher dosage has not been \ndemonstrated to increase the proportion of healthy adult \nnonresponders (70,71) or previous responders revaccinated as part \nof a clinical trial (62) who achieve vaccine-induced seroprotection. \nHowever, 3-dose revaccination with a higher dosage (40 \u00b5g) did \nimprove the proportion of nonresponders achieving anti-HBs \nlevels of \u226510 mIU/mL in one study (100% among 17 persons \nreceiving 40 \u00b5g dose versus 62.5% among 18 persons receiving \n10 \u00b5g dose, p = 0.015, Fisher\u2019s exact test) (70). Revaccination with \n>3 doses (i.e., >6 total doses) is not recommended (11).\nHBV Infection among Vaccinated and \nUnvaccinated HCP\nFrom 1983 to 2010, the number of HBV infections among \nHCP declined approximately 98%, from an estimated 17,000",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_61",
        "document_id": "rr6210",
        "text": "HCP declined approximately 98%, from an estimated 17,000 \ninfections to 263 acute HBV infections (considering that \noccupational history was assessed for 43.6% of cases and using \na correction factor of 10.5 to account for underreporting and \nasymptomatic infection) (10). The decrease in acute HBV \ninfection among HCP probably resulted from routine pre-\nexposure HepB vaccination and reduced risk for exposure \nthrough improvements in infection-control practices (28,72,73).\nAlthough few studies have evaluated the vaccination history \nof persons with acute hepatitis B (74), some cases of acute \nhepatitis B and chronic HBV infection can be expected in \nunvaccinated persons and among vaccine nonresponders. \nDuring 2005\u20132010, a total of 203 cases of persons with acute",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_62",
        "document_id": "rr6210",
        "text": "During 2005\u20132010, a total of 203 cases of persons with acute \nhepatitis B among HCP were reported to CDC\u2019s National \nNotifiable Diseases Surveillance System (NNDSS) (75). Six of \n17 patients with information on the development of chronic \nHBV infection developed chronic HBV infection (75). \nFollow-up of 67 (76.1%) of 88 HCP initially reported as having \na positive or unknown HepB vaccination history indicated that \n35 HCP reported vaccination with \u22653 HepB vaccine doses \n(seven had documentation to support the reported vaccination \nhistory) (75). Among the 35 HCP reporting vaccination with \n\u22653 HepB vaccine doses, one HCP demonstrated an immune \nresponse (i.e., anti-HBs \u226510 mlU/mL); the remaining 34 were \nnonresponders or had an unknown response status (75). Four",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_63",
        "document_id": "rr6210",
        "text": "nonresponders or had an unknown response status (75). Four \nof eight HCP with \u22653-dose HepB vaccination with information \ndeveloped chronic HBV infection; none of the four had complete \ndocumentation of \u22653 HepB vaccine doses (75). Postvaccination \nserologic testing was available for only one of seven HCPs with \ndocumentation of \u22653-doses of HepB vaccine; this HCP had \nan anti-HBs level <10 mIU/mL after 4 doses of vaccine (75).\nAlthough reported data did not enable identification of the \nmodes of transmission or information on receipt of postexposure \nprophylaxis, 28 (16.7%) of 168 HCP for whom data were \navailable reported an accidental stick or puncture with a \nneedle or other object contaminated with blood during the \n6 weeks through 6 months before illness, possibly representing",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_64",
        "document_id": "rr6210",
        "text": "6 weeks through 6 months before illness, possibly representing \noccupational acquisition of infection (75). Unrecognized \nexposures might have resulted in HBV infections among HCP \nwho did not report an exposure (2). Other risk factors for \nHBV exposure in the 6 weeks through 6 months before illness \n(i.e., injection drug use, men who have sex with men, multiple \nsex partners, contact with a hepatitis B case, dialysis patient, \nreceipt of blood transfusion, surgery, acupuncture, and tattoo \nreceipt) were present among 121 (59.6%) of 203 HCP, possibly \nsuggesting their exposures were not occupational (75).\nManaging HCP Vaccination and Serologic \nTest Results\nImmunization information systems (IIS) provide consolidated \nvaccination histories for use by vaccination providers in",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_65",
        "document_id": "rr6210",
        "text": "vaccination histories for use by vaccination providers in \nRecommendations and Reports\n10\t\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\ndetermining appropriate vaccinations (76). Accessing IIS for \nvaccination records might decrease unnecessary revaccination \namong HCP who no longer have records of HepB vaccination. \nIIS do not accept postvaccination anti-HBs test results (77). To \nreduce the cost and inconvenience of repeat anti-HBs testing \nwhen HCP are employed by different health-care facilities, \nCDC recommends that institutions consider systems for \nlong-term management of anti-HBs and other hepatitis B \nserologic test results. Mechanisms for tracking vaccination \nand hepatitis B serologic test results in health information",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_66",
        "document_id": "rr6210",
        "text": "and hepatitis B serologic test results in health information \ntechnology products could also reduce cost and inconvenience \nof repeat anti-HBs testing.\nPassive Prophylaxis of HBV Exposed \nHealth Care Personnel\nHepatitis B immune globulin\nHepatitis B immune globulin (HBIG) provides passive \nanti-HBs and temporary (i.e., 3\u20136 months) protection (15). \nHBIG is prepared from human plasma known to contain a \nhigh titer of anti-HBs. HBIG is typically used together with \nHepB vaccine for postexposure prophylaxis (15). For persons \nwho do not respond to HepB vaccine, HBIG administered \nalone is the primary method of protection after HBV exposure \n(15). The standard adult dose of HBIG is 0.06 mL/kg. HBIG \nis administered by intramuscular injection; an appropriate",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_67",
        "document_id": "rr6210",
        "text": "is administered by intramuscular injection; an appropriate \nmuscle mass (i.e., deltoid or gluteal) should be chosen in which \nto deliver the large volume of HBIG required and a needle \nlength appropriate for the HCP\u2019s size should be used. HBIG \ncan be administered simultaneously with HepB vaccine but \nat a different injection site (15).\nSafety\nThe plasma from which HBIG is prepared is screened for \nHBsAg, HCV, and HIV (15). The process used to prepare \nHBIG inactivates HBV, HCV, and HIV from the final product. \nNo evidence exists that HBV, HCV, or HIV has ever been \ntransmitted by HBIG thar is commercially available in the \nUnited States (15).\nSerious adverse effects from HBIG, when administered \nas recommended, are rare (1). Local pain and tenderness at",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_68",
        "document_id": "rr6210",
        "text": "as recommended, are rare (1). Local pain and tenderness at \nthe injection site, urticaria, and angioedema might occur; \nanaphylactic reactions, although rare, have been reported \nfollowing the injection of human immune globulin (IG) \npreparations (1). HBIG is not contraindicated for pregnant \n(1,78) or lactating women (1).\nEfficacy\nThe effectiveness of HBIG and HepB vaccine in various \npostexposure settings has been evaluated by prospective \nstudies. For perinatal exposure to a mother positive for \nboth HBsAg and HBeAg, a regimen combining HBIG and \ninitiation of the HepB vaccine series at birth is 85%\u201395% \neffective in preventing HBV infection (79,80). Regimens \ninvolving either multiple doses of HBIG alone or the HepB \nvaccine series alone are 70%\u201375% effective in preventing",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_69",
        "document_id": "rr6210",
        "text": "vaccine series alone are 70%\u201375% effective in preventing \nHBV infection when administered shortly after exposure \n(81). In the occupational setting, multiple doses of HBIG \nstarting within 1 week following percutaneous exposure to \nHBsAg-positive blood provide an estimated 75% protection \nfrom HBV infection (82\u201386). Administration of HBIG might \nprolong the incubation period of HBV infection among \npersons who develop infection (82,85,87,88). A comparison \nof the postexposure efficacy of the combination of HBIG and \nthe HepB vaccine series or HBIG alone has not been evaluated \nin the occupational setting (1). Whether the increased efficacy \nof HBIG added to HepB vaccine observed in the perinatal \nsetting, compared with HBIG alone, applies to adults exposed \noccupationally remains unknown.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_70",
        "document_id": "rr6210",
        "text": "setting, compared with HBIG alone, applies to adults exposed \noccupationally remains unknown.\nCost-Effectiveness Considerations\nTo examine the cost-effectiveness of various strategies for \nassessing HCP protection from hepatitis B, two economic \nmodels that yielded calculations of the incremental cost per \nquality-adjusted life-year (QALY) saved were developed. \nOne model represented an approach in which anti-HBs is \nmeasured on a pre-exposure basis, and HCP with anti-HBs \n<10 mIU/mL receive an additional dose of HepB vaccine, \nfollowed by repeat anti-HBs measurement. If anti-HBs \nremains <10 mIU/mL after the first revaccination dose, the \nHCP receives two additional revaccination doses of HepB \nvaccine followed by repeat anti-HBs measurement. Another",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_71",
        "document_id": "rr6210",
        "text": "vaccine followed by repeat anti-HBs measurement. Another \nmodel represented a postexposure management approach; \nat the time of exposure, the HCP is tested for anti-HBs and \nthe source patient is tested simultaneously for HBsAg, and \npostexposure prophylaxis would be administered on the basis \nof these results. Results from the two models were compared. \nA decision-tree analysis was used to combine all parameters \nand calculate the total intervention costs and probability of \ninfection. In addition, HBV infection-related costs and QALY \nloss (accounting for acute and asymptomatic infections and \na 6% probability of chronic infection) were determined from \nan existing model (89) and were considered for the HCP\u2019s \nremaining lifetime. The intervention time frame included a",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_72",
        "document_id": "rr6210",
        "text": "remaining lifetime. The intervention time frame included a \n1-year analysis and a multiyear analysis covering up to 10 years \nof exposure. A 3% annual discount rate was used, and all final \ncost figures were converted to 2010 U.S. dollars using the \nMedical Consumer Price Index.\nThe baseline cost-effectiveness models assumed that an ideal \n95% of HCP have initial and sustained protection against \nHBV infection after a primary \u22653-dose HepB vaccine series, \nRecommendations and Reports\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\t\n11\nirrespective of the presence of detectable anti-HBs. Ninety-five \npercent protection was derived from the proportion of persons \naged <40 years, including term newborns that have measurable \nanti-HBs \u226510 mIU/mL soon after a primary vaccination series.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_73",
        "document_id": "rr6210",
        "text": "anti-HBs \u226510 mIU/mL soon after a primary vaccination series. \nApproximately 18\u201325 years after vaccination, approximately \n20% of HCP (vaccinated at age <1 year) or approximately \n80% of HCP (vaccinated at age \u22651 year) retain anti-HBs \n\u226510 mIU/mL. The model did not account for unrecognized \nexposures, as probability data for unrecognized exposures are not \navailable, or suboptimal vaccine coverage that exists among HCP.\nFor pre-exposure anti-HBs testing followed by revaccination \nand retesting, if necessary, compared with doing nothing, the \nincremental cost per QALY saved was $4,542,467 for trainees \nand $3,149,183 for nontrainees at year one, and decreased \nto $893,619 and $796,140, respectively, over 10 years. \nThis approach is expected to result in 3.7 and 1.6 visits to",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_74",
        "document_id": "rr6210",
        "text": "This approach is expected to result in 3.7 and 1.6 visits to \noccupational health for trainees and nontrainees, respectively. \nThe expected number of infections is 0.7 per 100,000 and 0.4 \nper 100,000 for trainees and nontrainees, respectively. For an \napproach relying upon postexposure management, compared \nwith doing nothing, the incremental cost per QALY saved was \n$2,270,801 for trainees and $1,610,998 for nontrainees at year \none, and decreased to $917,859 and $1,114,364 respectively, \nover 10 years. The expected number of infections is 3.0 per \n100,000 and 1.7 per 100,000 for trainees and nontrainees, \nrespectively. Although an approach relying upon postexposure \nmanagement might be less costly per QALY saved initially for",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_75",
        "document_id": "rr6210",
        "text": "management might be less costly per QALY saved initially for \nmany institutions, pre-exposure anti-HBs testing with possible \nrevaccination becomes more cost-effective compared with a \npostexposure approach over time.\nSensitivity analyses demonstrated that cost-effectiveness \nimproves in settings where a greater proportion of source \npatients are HBsAg-positive and among HCP with higher risk \nfor exposure (e.g., surgeons). Cost-effectiveness can change \nas new antivirals become available for treatment of HBV \ninfection. Vaccinating previously unvaccinated HCP trainees \nfollowed by postvaccination serologic testing, compared with \ndoing nothing, has an incremental cost per QALY saved of \n$374,646 at year one and $51,537 over 10 years, accounting",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_76",
        "document_id": "rr6210",
        "text": "$374,646 at year one and $51,537 over 10 years, accounting \nfor direct costs to the health-care system and direct medical \ncosts of hepatitis B-related illness and complications.\nRecommendations\nPre-Exposure Management\nEducation and Infrastructure\nAt the time of hire or matriculation, health-care providers \nand health-care institutions should provide training to HCP \nto improve recognition and encourage timely reporting of \nblood and body fluid exposures. The possibility that the \npostexposure evaluation will cause the HCP to have time lost \nfrom work should not be a barrier to reporting. Institutions \nshould ensure that HCP have rapid access to postexposure \ntesting and prophylaxis, including HBIG and HepB vaccine.\nSerologic Testing for HBV Infection",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_77",
        "document_id": "rr6210",
        "text": "testing and prophylaxis, including HBIG and HepB vaccine.\nSerologic Testing for HBV Infection\nTesting unvaccinated HCP for HBV infection is not generally \nindicated for persons being evaluated for hepatitis B protection \nbecause of occupational risk. Prevaccination serologic testing \nis indicated for all persons born in geographic regions with \nHBsAg prevalence of \u22652% (e.g., much of Eastern Europe, Asia, \nAfrica, the Middle East, and the Pacific Islands) and certain \nindigenous populations from countries with overall low HBV \nendemicity (<2%); persons with behavioral exposures to HBV \n(e.g., men who have sex with men and past or current injection \ndrug users); persons receiving cytotoxic or immunosuppressive \ntherapy; and persons with liver disease of unknown etiology.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_78",
        "document_id": "rr6210",
        "text": "therapy; and persons with liver disease of unknown etiology.\n HBV endemicity (HBsAg prevalence) can be described as \nlow (<2%), moderate (2%\u2013<8%), and high (\u22658%). Because \ncertain persons might have been infected with HBV before they \nreceived HepB vaccination, HBsAg testing is recommended \nregardless of vaccination history for persons born in geographic \nregions with HBsAg prevalence of \u22652%, U.S.-born persons not \nvaccinated as infants whose parents were born in regions with \nhigh HBV endemicity (HBsAg prevalence) (\u22658%), persons \nwho received HepB vaccination as adolescents or adults after \nthe initiation of risk behaviors (12), and persons who are \nHIV-positive or who receive hemodialysis (11).\nTesting HCP at risk for HBV infection should consist of a",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_79",
        "document_id": "rr6210",
        "text": "Testing HCP at risk for HBV infection should consist of a \nserologic assay for HBsAg, in addition to either anti-HBc or \nanti-HBs (11,12). For unvaccinated HCP at risk for previous \nHBV infection, blood should be drawn for testing before the \nfirst dose of vaccine is administered.\nVaccination\nAll HCP whose work-, training-, and volunteer-related \nactivities involve reasonably anticipated risk for exposure to \nblood or body fluids should be vaccinated with a complete, \n\u22653-dose HepB vaccine series. OSHA mandates that \nvaccination be available for employees within 10 days of \ninitial assignment (27). HCP trainees should complete the \nseries before the potential for exposure with blood or body \nfluids, when possible, as higher risk has been reported during",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_80",
        "document_id": "rr6210",
        "text": "fluids, when possible, as higher risk has been reported during \nprofessional training (e.g., residency training).\nIncompletely vaccinated HCP should receive additional \ndose(s) to complete the vaccine series (15). The vaccine series \ndoes not need to be restarted for HCP with an incomplete \nRecommendations and Reports\n12\t\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\nseries; however, minimum dosing intervals should be heeded \n(15). Minimum dosing intervals are 4 weeks between the first \nand second dose, 8 weeks between the second and third dose, \nand 16 weeks between the first and third dose (15).\nHCP lacking documentation of HepB vaccination should \nbe considered unvaccinated (when documentation for HepB \nvaccine doses is lacking) or incompletely vaccinated (when",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_81",
        "document_id": "rr6210",
        "text": "vaccine doses is lacking) or incompletely vaccinated (when \ndocumentation for some HepB vaccine doses is lacking) and \nshould receive additional doses to complete a documented \nHepB series. Health-care institutions are encouraged to seek \ndocumentation of \u201cmissing\u201d HepB doses in IIS, when feasible, \nto avoid unnecessary vaccination.\nOSHA mandates that HCP who refuse HepB vaccination \nsign a declination statement (http://www.osha.gov/pls/\noshaweb/owadisp.show_document?p_id=10052&p_\ntable=STANDARDS). HCP refusing HepB vaccination can \nobtain vaccination at a later date at no expense if the HCP is \nstill covered under OSHA\u2019s Bloodborne Pathogens Standard. \nHealth-care institutions should encourage HepB vaccination \namong HCP to improve HBV protection and to achieve the",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_82",
        "document_id": "rr6210",
        "text": "among HCP to improve HBV protection and to achieve the \nHealthy People 2020 target of 90% vaccination (66).\nPostvaccination Serologic Testing\nHCP who have written documentation of a complete, \n\u22653-dose HepB vaccine series and subsequent postvaccination \nanti-HBs \u226510 mIU/mL are considered hepatitis B immune. \nImmunocompetent persons have long-term protection against \nHBV and do not need further periodic testing to assess \nanti-HBs levels (Figure 6).\nAll HCP recently vaccinated or recently completing HepB \nvaccination who are at risk for occupational blood or body \nfluid exposure should undergo anti-HBs testing. Anti-HBs \ntesting should be performed 1\u20132 months after administration \nof the last dose of the vaccine series when possible. HCP with",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_83",
        "document_id": "rr6210",
        "text": "of the last dose of the vaccine series when possible. HCP with \ndocumentation of a complete \u22653-dose HepB vaccine series \nbut no documentation of anti-HBs \u226510 mIU/mL who are \nat risk for occupational blood or body fluid exposure might \nundergo anti-HBs testing upon hire or matriculation. Testing \nshould use a quantitative method that allows detection of \nthe protective concentration of anti-HBs (\u226510 mIU/mL) \n(e.g., enzyme-linked immunosorbent assay [ELISA]).\n\u2022 Completely vaccinated HCP with anti-HBs \u226510 mIU/mL \nare considered hepatitis B immune. Immunocompetent \npersons have long-term protection and do not need further \nperiodic testing to assess anti-HBs levels.\n\u2022 Completely vaccinated HCP with anti-HBs <10 mIU/mL \nshould receive an additional dose of HepB vaccine, followed",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_84",
        "document_id": "rr6210",
        "text": "should receive an additional dose of HepB vaccine, followed \nby anti-HBs testing 1\u20132 months later. HCP whose \nanti-HBs remains <10 mIU/mL should receive 2 additional \nvaccine doses (usually 6 doses total), followed by repeat \nanti-HBs testing 1\u20132 months after the last dose. Alternatively, \nit might be more practical for very recently vaccinated HCP \nwith anti-HBs <10 mIU/mL to receive 3 consecutive \nadditional doses of HepB vaccine (usually 6 doses total), \nfollowed by anti-HBs testing 1\u20132 months after the last dose.\nStandard Precautions and Advising HCP to \nReport Exposures\nAll HCP should adhere to infection-control guidelines \nand follow Standard Precautions (90), including the use of \nengineering and work-practice controls, to reduce the risk",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_85",
        "document_id": "rr6210",
        "text": "engineering and work-practice controls, to reduce the risk \nfor blood or body fluid exposure. All HCP, including those \nwho have demonstrated protection against HBV, should be \nadvised to immediately report blood or body fluid exposures to \noccupational health for evaluation of the appropriate measures \nto prevent transmission of bloodborne pathogens (including \nHIV, hepatitis C, and hepatitis B).\nPostexposure Management\nInitial Postexposure Management\nWounds and skin sites that have been in contact with blood \nor body fluids should be washed with soap and water; mucous \nmembranes should be flushed with water. Using antiseptics \n(e.g., 2%\u20134% chlorhexidine) for wound care or expressing fluid \nby squeezing the wound further have not been shown to reduce",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_86",
        "document_id": "rr6210",
        "text": "by squeezing the wound further have not been shown to reduce \nthe risk for HBV transmission; however, the use of antiseptics \nis not contraindicated. The application of caustic agents \n(e.g., bleach) or the injection of antiseptics or disinfectants into \nthe wound is not recommended.\nProcedures should be followed for testing known source \npersons, including obtaining informed consent, in accordance \nwith applicable laws. Source patients determined to be \nHBsAg-positive should be referred for appropriate management \nand should be reported to the state or local health department. \nWhen a source patient is unknown (e.g., as occurs from a \npuncture with a needle in the trash), the exposed HCP should \nbe managed as if the source patient were HBsAg-positive.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_87",
        "document_id": "rr6210",
        "text": "be managed as if the source patient were HBsAg-positive. \nTesting needles and other sharp instruments implicated in an \nexposure is not recommended, regardless of whether the source \npatient is known or unknown. The reliability and interpretation \nof findings in such circumstances are unknown, and testing \ncould be hazardous to persons handling the sharp instrument. \nExposures involving human bites should be managed with the \nknowledge that both the person being bitten and the person \nwho engaged in biting were potentially exposed.\nInstitutions should ensure that HCP have timely access \nto postexposure management and prophylaxis, including \nRecommendations and Reports\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\t\n13\nThis figure provides guidance for pre-exposure evaluation \nof health",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_88",
        "document_id": "rr6210",
        "text": "13\nThis figure provides guidance for pre-exposure evaluation \nof health\n-care pers\nonnel who\n have been\n complete\nly vaccina\nted with \n\u22653 dose He\npB vaccine series and who have not\n had postvaccination serologic tes\nting.\nSource: Adapted from CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations \nof the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR 2006;55(No. RR-16).\n*\tShould be performed 1\u20132 months after the last dose of vaccine using a quantitative method that allows detection of the protective concentration of anti-HBs \n(\u226510 mIU/mL) (e.g., enzyme-linked immunosorbent assay [ELISA]).",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_89",
        "document_id": "rr6210",
        "text": "(\u226510 mIU/mL) (e.g., enzyme-linked immunosorbent assay [ELISA]).\n\u2020\tA nonresponder is defined as a person with anti-HBs <10 mIU/mL after \u22656 doses of HepB vaccine. Persons who do not have a protective concentration of anti-HBs \nafter revaccination should be tested for HBsAg. If positive, the person should receive appropriate management or vaccination.\nFIGURE 6. Pre-exposure evaluation for health-care personnel previously vaccinated with complete, \u22653-dose HepB vaccine series who have \nnot had postvaccination serologic testing* \nRecommendations and Reports\n14\t\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\nHBIG and HepB vaccine. For exposed HCP thought to \nbe susceptible to HBV infection, HBIG and HepB vaccine \nshould be administered as soon as possible after an exposure",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_90",
        "document_id": "rr6210",
        "text": "should be administered as soon as possible after an exposure \nwhen indicated. The effectiveness of HBIG when administered \n>7 days after percutaneous, mucosal, or nonintact skin \nexposures is unknown. HBIG and HepB vaccine can be \nadministered simultaneously at separate injection sites.\nAnti-HBs testing of HCP who received HBIG should be \nperformed after anti-HBs from HBIG is no longer detectable \n(6 months after administration) (11). Anti-HBs testing should \nbe performed using a method that allows detection of the \nprotective concentration of anti-HBs (\u226510 mIU/mL) (Table 2).\nManaging Vaccinated HCP\nFor vaccinated HCP (who have written documentation of \na complete, \u22653-dose HepB vaccine series) with subsequent \ndocumented anti-HBs \u226510 mIU/mL, testing the source patient",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_91",
        "document_id": "rr6210",
        "text": "documented anti-HBs \u226510 mIU/mL, testing the source patient \nfor HBsAg is unnecessary. No postexposure management \nfor HBV is necessary, regardless of the source patient\u2019s \nHBsAg status.\nFor vaccinated HCP (who have written documentation of \nHepB vaccination) with anti-HBs <10 mIU/mL after two \ncomplete, \u22653-dose HepB vaccine series, the source patient \nshould be tested for HBsAg as soon as possible after the \nexposure. If the source patient is HBsAg-positive or has \nunknown HBsAg status, the HCP should receive 2 doses \nof HBIG (1,11). The first dose should be administered as \nsoon as possible after the exposure, and the second dose \nshould be administered 1 month later. If the source patient is \nHBsAg-negative, neither HBIG nor HepB vaccine is necessary.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_92",
        "document_id": "rr6210",
        "text": "HBsAg-negative, neither HBIG nor HepB vaccine is necessary.\nFor vaccinated HCP (who have written documentation of \na complete, \u22653-dose HepB vaccine series) without previous \nanti-HBs testing, the HCP should be tested for anti-HBs and \nthe source patient (if known) should be tested for HBsAg as \nsoon as possible after the exposure. Testing the source patient \nand the HCP should occur simultaneously; testing the source \npatient should not be delayed while waiting for the HCP \nanti-HBs test results, and likewise, testing the HCP should not \nbe delayed while waiting for the source patient HBsAg results.\nTABLE 2. Postexposure management of health-care personnel after occupational percutaneous and mucosal exposure to blood and body",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_93",
        "document_id": "rr6210",
        "text": "fluids, by health-care personnel HepB vaccination and response status\nHealth-care personnel status\nPostexposure testing\nPostexposure prophylaxis\nPostvaccination \nserologic \ntesting\u2020\nSource patient\n(HBsAg)\nHCP testing\n(anti-HBs)\nHBIG*\nVaccination\nDocumented responder\u00a7 after \ncomplete series (\u22653 doses)\nNo action needed\nDocumented nonresponder\u00b6 \nafter 6 doses\nPositive/unknown\n\u2014**\nHBIG x2 separated \nby 1 month\n\u2014\nNo\nNegative\nNo action needed\nResponse unknown after \n3 doses\nPositive/unknown\n<10mIU/mL**\nHBIG x1\nInitiate \nrevaccination\nYes\nNegative\n<10mIU/mL\nNone\nAny result\n\u226510mIU/mL\nNo action needed\nUnvaccinated/incompletely \nvaccinated or vaccine refusers\nPositive/unknown\n\u2014**\nHBIG x1\nComplete \nvaccination\nYes\nNegative\n\u2014\nNone\nComplete \nvaccination\nYes",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_94",
        "document_id": "rr6210",
        "text": "Positive/unknown\n\u2014**\nHBIG x1\nComplete \nvaccination\nYes\nNegative\n\u2014\nNone\nComplete \nvaccination\nYes\nAbbreviations: HCP = health-care personnel; HBsAg = hepatitis B surface antigen; anti-HBs = antibody to hepatitis B surface antigen; HBIG = hepatitis B immune globulin.\n\t *\tHBIG should be administered intramuscularly as soon as possible after exposure when indicated. The effectiveness of HBIG when administered >7 days after \npercutaneous, mucosal, or nonintact skin exposures is unknown. HBIG dosage is 0.06 mL/kg.\n\t \u2020\tShould be performed 1\u20132 months after the last dose of the HepB vaccine series (and 4\u20136 months after administration of HBIG to avoid detection of passively",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_95",
        "document_id": "rr6210",
        "text": "administered anti-HBs) using a quantitative method that allows detection of the protective concentration of anti-HBs (\u226510 mIU/mL). \n\t \u00a7\tA responder is defined as a person with anti-HBs \u226510 mIU/mL after \u22653 doses of HepB vaccine.\n\t \u00b6\tA nonresponder is defined as a person with anti-HBs <10 mIU/mL after \u22656 doses of HepB vaccine.\n\t**\tHCP who have anti-HBs <10mIU/mL, or who are unvaccinated or incompletely vaccinated, and sustain an exposure to a source patient who is HBsAg-positive or \nhas unknown HBsAg status, should undergo baseline testing for HBV infection as soon as possible after exposure, and follow-up testing approximately 6 months \nlater. Initial baseline tests consist of total anti-HBc; testing at approximately 6 months consists of HBsAg and total anti-HBc.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_96",
        "document_id": "rr6210",
        "text": "Recommendations and Reports\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\t\n15\n\u2022 If the HCP has anti-HBs <10 mIU/mL and the source \npatient is HBsAg-positive or has unknown HBsAg status, \nthe HCP should receive 1 dose of HBIG and be revaccinated \nas soon as possible after the exposure. The HCP should \nthen receive the second 2 doses to complete the second \nHepB vaccine series (6 doses total when accounting for the \noriginal 3-dose series) according to the vaccination \nschedule. To document the HCP\u2019s vaccine response status \nfor future exposures, anti-HBs testing should be performed \n1\u20132 months after the last dose of vaccine.\n\u2022 If the HCP has anti-HBs <10 mIU/mL and the source \npatient is HBsAg-negative, the HCP should receive an",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_97",
        "document_id": "rr6210",
        "text": "patient is HBsAg-negative, the HCP should receive an \nadditional HepB vaccine dose, followed by repeat anti-HBs \ntesting 1\u20132 months later. HCP whose anti-HBs remains \n<10 mIU/mL should undergo revaccination with 2 more \ndoses (6 doses total when accounting for the original 3-dose \nseries). To document the HCP\u2019s vaccine response status for \nfuture exposures, anti-HBs testing should be performed \n1\u20132 months after the last dose of vaccine.\n\u2022 If the HCP has anti-HBs \u226510 mIU/mL at the time of the \nexposure, no postexposure HBV management is necessary, \nregardless of the source patient\u2019s HBsAg status.\nManaging HCP Who Lack Documentation of \nVaccination, are Unvaccinated or \nIncompletely Vaccinated\nFor unvaccinated or incompletely vaccinated HCP (including",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_98",
        "document_id": "rr6210",
        "text": "Incompletely Vaccinated\nFor unvaccinated or incompletely vaccinated HCP (including \nthose who refused vaccination), the source patient should be \ntested for HBsAg as soon as possible after the exposure. Testing \nunvaccinated or incompletely vaccinated HCP for anti-HBs is \nnot necessary and is potentially misleading, because anti-HBs \n\u226510 mIU/mL as a correlate of vaccine-induced protection has \nonly been determined for persons who have completed an \napproved vaccination series (15,42).\n\u2022 If the source patient is HBsAg-positive or has unknown \nHBsAg status, the HCP should receive 1 dose of HBIG \nand 1 dose of HepB vaccine administered as soon as \npossible after the exposure. The HCP should complete \nthe HepB vaccine series according to the vaccination",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_99",
        "document_id": "rr6210",
        "text": "the HepB vaccine series according to the vaccination \nschedule. To document the HCP\u2019s vaccine response status \nfor future exposures, anti-HBs testing should be performed \napproximately 1\u20132 months after the last dose of vaccine. \nBecause anti-HBs testing of HCP who received HBIG \nshould be performed after anti-HBs from HBIG is no \nlonger detectable (6 months after administration), it will \nlikely be necessary to defer anti-HBs testing for a period \nlonger than 1\u20132 months after the last vaccine dose.\n\u2013\u2013 HCP with anti-HBs \u226510 mIU/mL after receipt of the \nprimary vaccine series are considered immune. \nImmunocompetent persons have long-term protection \nand do not need further periodic testing to assess anti-\nHBs levels.\n\u2013\u2013 HCP with anti-HBs <10 mIU/mL after receipt of the",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_100",
        "document_id": "rr6210",
        "text": "HBs levels.\n\u2013\u2013 HCP with anti-HBs <10 mIU/mL after receipt of the \nprimary series should be revaccinated. For these HCP, \nadministration of a second complete 3-dose series on an \nappropriate schedule, followed by anti-HBs testing \n1\u20132 months after the third dose, usually is more practical \nthan conducting serologic testing after each additional \ndose of vaccine. To document the HCP\u2019s vaccine response \nstatus for future exposures, anti-HBs testing should be \nperformed 1\u20132 months after the last dose of vaccine.\n\u2022 If the source patient is HBsAg-negative, the HCP should \ncomplete the HepB vaccine series according to the \nvaccination schedule. To document the HCP\u2019s vaccine \nresponse status for future exposures, anti-HBs testing \nshould be performed approximately 1\u20132 months after the",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_101",
        "document_id": "rr6210",
        "text": "should be performed approximately 1\u20132 months after the \nlast dose of vaccine.\n\u2013\u2013 HCP with anti-HBs \u226510 mIU/mL after receipt of the \nprimary vaccine series are considered immune. \nImmunocompetent persons have long-term protection \nand do not need further periodic testing to assess anti-\nHBs levels.\n\u2013\u2013 HCP with anti-HBs <10 mIU/mL after receipt of the \nprimary series should be revaccinated. For these HCP, \nadministration of a second complete 3-dose series on \nan appropriate schedule, followed by anti-HBs testing \n1\u20132 months after the third dose, usually is more \npractical than conducting serologic testing after each \nadditional dose of vaccine. To document the HCP\u2019s \nvaccine response status for future exposures, anti-HBs \ntesting should be performed 1\u20132 months after the last",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_102",
        "document_id": "rr6210",
        "text": "testing should be performed 1\u20132 months after the last \ndose of vaccine.\nTesting of HCP Exposed to an HBsAg-Positive or \nUnknown Source\nHCP who have anti-HBs <10 mIU/mL, or who are \nunvaccinated or incompletely vaccinated, and who sustain a \npercutaneous, mucosal, or nonintact skin exposure to a source \npatient who is HBsAg-positive or has unknown HBsAg status \nshould undergo baseline testing for HBV infection as soon as \npossible after the exposure, and follow-up testing approximately \n6 months later. Testing immediately after the exposure should \nconsist of total anti-HBc, and follow-up testing approximately \n6 months later should consist of HBsAg and total anti-HBc.\nHCP exposed to a source patient who is HBsAg-positive \nor has unknown HBsAg status do not need to take special",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_103",
        "document_id": "rr6210",
        "text": "or has unknown HBsAg status do not need to take special \nprecautions to prevent secondary transmission during the \nfollow-up period; however, they should refrain from donating \nblood, plasma, organs, tissue, or semen (1). The exposed \nHCP does not need to modify sexual practices or refrain from \nRecommendations and Reports\n16\t\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\nbecoming pregnant (1). If an exposed HCP is breast feeding, \nshe does not need to discontinue (1). No modifications to \nan exposed HCP\u2019s patient-care responsibilities are necessary \nto prevent transmission to patients based solely on exposure \nto a source patient who is HBsAg-positive or has unknown \nHBsAg status.\nVaccine Nonresponders\nVaccinated HCP whose anti-HBs remains <10 mIU/mL after",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_104",
        "document_id": "rr6210",
        "text": "HBsAg status.\nVaccine Nonresponders\nVaccinated HCP whose anti-HBs remains <10 mIU/mL after \nrevaccination (i.e., after receiving a total of 6 doses) should \nbe tested for HBsAg and anti-HBc to determine infection \nstatus. Those determined not to be HBV infected (vaccine \nnonresponders) should be considered susceptible to HBV \ninfection. No specific work restrictions are recommended for \nvaccine nonresponders (91).\nDocumentation\nHealth-care institutions should maintain records, ideally \nelectronic records that are easily retrievable following exposures, \nof documented vaccination histories and serologic test results for \nreference in managing occupational exposures, and to provide \nto other health-care institutions if requested by the HCP. The",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_105",
        "document_id": "rr6210",
        "text": "to other health-care institutions if requested by the HCP. The \nvaccination information should be entered into an IIS accepting \nrecords from adult vaccination, if available. HCP should be \nprovided a copy of HepB vaccination and anti-HBs testing \nresults and encouraged to keep them with their personal health \nrecords so they can readily be made available to future employers.\nHCP with HBV Infection\nHCP who are positive for HBsAg should be counseled \nhow to prevent HBV transmission to others and referred for \nfurther evaluation (92). Those who perform exposure-prone \nprocedures should be advised regarding the procedures they \ncan perform safely as per updated CDC recommendations \nfor the management of HBsAg-positive health-care providers",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_106",
        "document_id": "rr6210",
        "text": "for the management of HBsAg-positive health-care providers \nand students (11,13). Chronic hepatitis B infection in itself \nshould not preclude the practice or study of medicine, surgery, \ndentistry, or allied health professions (13).\nFuture Studies\nNational surveillance systems to accurately assess the burden \nof hepatitis B among HCP and health-care facility databases \ntracking occupational exposures among HCP are important for \nmonitoring the changing epidemiology of occupationally acquired \nHBV infections and other bloodborne pathogens. Systems and \ndatabases could ideally be electronically linked to employee \nhealth records and should include results that identify HepB \nvaccine responders and nonresponders, the nature and HBV",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_107",
        "document_id": "rr6210",
        "text": "vaccine responders and nonresponders, the nature and HBV \nstatus of the exposure source and postexposure management, \nand the HCP\u2019s anti-HBs level. Appropriate safeguards should be \nin place to protect the privacy of the health information. Data \ncollection should be representative of HCP in a variety of settings \n(e.g., acute care, long-term care, and dialysis), including settings \nwith frequent staff turnover. Studies assessing HBV transmission \namong all HCP exposed to an HBsAg-positive source, regardless \nof vaccination history or anti-HBs levels, approximately \n6 months after an exposure will help to inform duration of \nvaccine protection. Surveillance activities for acute hepatitis B \ninfection should continue to ascertain occupation among cases,",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_108",
        "document_id": "rr6210",
        "text": "infection should continue to ascertain occupation among cases, \nin addition to HepB vaccination history. Long-term follow-up \nstudies assessing disease incidence and duration of anti-HBs \namong persons vaccinated as infants and older adults, including \npersons who received booster doses subsequent to the primary \nvaccine series and persons from HBV-endemic areas, also might \nprovide information on duration of vaccine-induced protection. \nOther subject areas that would benefit from research include \nefficacy and cost-effectiveness of antiviral agents for postexposure \nprophylaxis, immunogenicity of higher dosage or new vaccines \nfor revaccinating vaccine nonresponders, and an examination of \nthe future role of postexposure hepatitis B virus deoxyribonucleic \nacid (HBV DNA) testing.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_109",
        "document_id": "rr6210",
        "text": "the future role of postexposure hepatitis B virus deoxyribonucleic \nacid (HBV DNA) testing.\nAcknowledgments\nThe following persons were consulted during the drafting of \nthese recommendations: Thomas J. Hoerger, PhD, Christina \nLudlow-Bradley, Research Triangle Institute, International, Durham, \nNorth Carolina; Henry Roberts, PhD, Emily Smith, MPH, Steven \nVeselsky, MPH, National Center for HIV/AIDS, Viral Hepatitis, \nSTD, and TB Prevention; Donna Weaver, RN, National Center for \nImmunization and Respiratory Diseases; Tara MacCannell, PhD, \nRonda Sinkowitz-Cochran, MPH, National Center for Emerging \nand Zoonotic Infectious Diseases.\nReferences\n\t 1.\tUS Public Health Service. Updated U.S. Public Health Service guidelines \nfor the management of occupational exposures to HBV, HCV, and HIV",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_110",
        "document_id": "rr6210",
        "text": "for the management of occupational exposures to HBV, HCV, and HIV \nand recommendations for postexposure prophylaxis. MMWR \n2001;29:50(No. RR-11).\n\t 2.\tRosenberg JL, Jones DP, Lipitz LR, Kirsner JB. Viral hepatitis: an \noccupational hazard to surgeons. JAMA 1973;223:395\u2013400. \n\t 3.\tTrinkoff AM, Le R, Geiger-Brown J, Lipscomb J. Work schedule, needle \nuse, and needlestick injuries among registered nurses. Infect Control \nHosp Epidemiol 2007;28:156\u201364. \n\t 4.\tBeltrami EM, Williams IT, Shapiro CN, Chamberland ME. Risk and \nmanagement of blood-borne infections in health care workers. Clin \nMicrobiol Rev 2000;13:385\u2013407. \n\t 5.\tCDC. Recommendation of the Immunization Practices Advisory \nCommittee (ACIP). Inactivated hepatitis B virus vaccine. MMWR \n1982;31:317\u201322, 27\u20138.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_111",
        "document_id": "rr6210",
        "text": "Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR \n1982;31:317\u201322, 27\u20138.\n\t 6.\tAverhoff F, Mahoney F, Coleman P, et al. Immunogenicity of hepatitis B \nvaccines. Implications for persons at occupational risk of hepatitis B \nvirus infection. Am J Prev Med 1998;15:1\u20138. \n\t 7.\tHadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity \nand efficacy of hepatitis B vaccine in homosexual men. N Engl J Med \n1986;315:209\u201314. \nRecommendations and Reports\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\t\n17\n\t 8.\tCDC. Update on adult immunization: recommendations of the \nAdvisory Committee on Immunization Practices (ACIP). MMWR 1991;\u200b\n40(No. RR-12).\n\t 9.\tCDC. Immunization of health-care workers: recommendations of the \nAdvisory Committee on Immunization Practices (ACIP) and the",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_112",
        "document_id": "rr6210",
        "text": "Advisory Committee on Immunization Practices (ACIP) and the \nHospital Infection Control Practices Advisory Committee (HICPAC). \nMMWR 1997;46(No. RR-18).\n\t10.\tCDC. Viral hepatitis statistics and surveillance. Available at http://\nwww.cdc.gov/hepatitis/statistics/index.htm.\n\t11.\tCDC. Immunization of health-care personnel: recommendations of the \nAdvisory Committee on Immunization Practices (ACIP). MMWR \n2011;60(No. RR-7).\n\t12.\tCDC. Recommendations for identification and public health management \nof persons with chronic hepatitis B virus infection. MMWR 2008;\u200b\n57(No. RR-8).\n\t13.\tCDC. Updated CDC recommendations for the management of \nhepatitis B virus-infected health-care providers and students. MMWR \n2012;61(No. RR-3).",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_113",
        "document_id": "rr6210",
        "text": "hepatitis B virus-infected health-care providers and students. MMWR \n2012;61(No. RR-3).\n\t14.\tCDC. Updated US Public Health Service guidelines for the management \nof occupational exposures to HIV and recommendations for postexposure \nprophylaxis. MMWR 2005;54(No. RR-9).\n\t15. CDC. A comprehensive immunization strategy to eliminate transmission \nof hepatitis B virus infection in the United States: recommendations of \nthe Advisory Committee on Immunization Practices (ACIP) part II: \nimmunization of adults. MMWR 2006;55(No. RR-16); quiz.\n\t16.\tCDC. Hepatitis B virus: a comprehensive strategy for eliminating \ntransmission in the United States through universal childhood vaccination: \nrecommendations of the Advisory Committee on Immunization Practices \n(ACIP). MMWR 1991;40(No. RR-13).",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_114",
        "document_id": "rr6210",
        "text": "(ACIP). MMWR 1991;40(No. RR-13).\n\t17.\tCDC. 2012 Case definitions: Nationally notifiable conditions infectious \nand non-infectious cases. Atlanta, GA: CDC; 2012.\n\t18.\tHyams KC. Risks of chronicity following acute hepatitis B virus \ninfection: a review. Clin Infect Dis 1995;20:992\u20131000. \n\t19.\tWasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of \nhepatitis B virus infection in the United States in the era of vaccination. \nJ Infect Dis 2010;202:192\u2013201. \n\t20.\tLy KN, Xing J, Klevens RM, et al. The increasing burden of mortality \nfrom viral hepatitis in the United States between 1999 and 2007. Ann \nIntern Med 2012;156:271\u20138. \n\t21.\tCDC. National, state, and local area vaccination coverage among children \naged 19\u201335 months\u2014United States, 2011. MMWR 2012;61:689\u201396.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_115",
        "document_id": "rr6210",
        "text": "aged 19\u201335 months\u2014United States, 2011. MMWR 2012;61:689\u201396.\n\t22.\tCDC. National and state vaccination coverage among adolescents aged \n13\u201317 years\u2014United States, 2011. MMWR 2012;61:671\u20137.\n\t23.\tCDC. Noninfluenza vaccination coverage among adults\u2014United States, \n2011. MMWR 2013;62:66\u201372.\n\t24.\tBond WW, Favero MS, Petersen NJ, et al. Survival of hepatitis B virus \nafter drying and storage for one week. Lancet 1981;1:550\u20131. \n\t25.\tGaribaldi RA, Hatch FE, Bisno AL, Hatch MH, Gregg MB. Nonparenteral \nserum hepatitis: report of an outbreak. JAMA 1972;220:963\u20136. \n\t26.\tWerner BG, Grady GF. Accidental hepatitis-B-surface-antigen-positive \ninoculations: use of e antigen to estimate infectivity. Ann Intern Med \n1982;97:367\u20139. \n\t27.\tUS Department of Labor. Occupational Health and Safety Administration.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_116",
        "document_id": "rr6210",
        "text": "1982;97:367\u20139. \n\t27.\tUS Department of Labor. Occupational Health and Safety Administration. \nAvailable at http://www.osha.gov.\n\t28.\tUniversity of Virginia Health System. International healthcare worker \nsafety center. Available at http://www.healthsystem.virginia.edu/pub/\nepinet/home.html.\n\t29.\tBoal WL, Leiss JK, Sousa S, et al. The national study to prevent blood \nexposure in paramedics: exposure reporting. Am J Ind Med 2008;51:213\u201322. \n\t30.\tGershon RR, Pearson JM, Sherman MF, et al. The prevalence and risk \nfactors for percutaneous injuries in registered nurses in the home health \ncare sector. Am J Infect Control 2009;37:525\u201333. \n\t31.\tGershon RR, Qureshi KA, Pogorzelska M, et al. Non-hospital based \nregistered nurses and the risk of bloodborne pathogen exposure. Ind",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_117",
        "document_id": "rr6210",
        "text": "registered nurses and the risk of bloodborne pathogen exposure. Ind \nHealth 2007;45:695\u2013704. \n\t32.\tLipscomb J, Sokas R, McPhaul K, et al. Occupational blood exposure \namong unlicensed home care workers and home care registered nurses: \nare they protected? Am J Ind Med 2009;52:563\u201370. \n\t33.\tDement JM, Epling C, Ostbye T, Pompeii LA, Hunt DL. Blood and \nbody fluid exposure risks among health care workers: results from the \nDuke Health and Safety Surveillance System. Am J Ind Med 2004;\u200b\n46:637\u201348. \n\t34.\tCDC. 2000\u20132012 exposure logs at three healthcare systems in the United \nStates. Personal Communication, Sarah Schillie.\n\t35.\tWang S, editor. Hepatitis B collaborative care model: implementation at \na community health center. Healthfirst 2011 fall symposium integrating",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_118",
        "document_id": "rr6210",
        "text": "a community health center. Healthfirst 2011 fall symposium integrating \nhealthcare: planning and systems to improve health outcomes; 2011.\n\t36.\tHadler SC, Margolis HS. Hepatitis B immunization: vaccine types, \nefficacy, and indications for immunization. Curr Clin Top Infect Dis \n1992;12:282\u2013308.\n\t37.\tStratton K, Ford A, Rusch E, Clayton EW. Adverse effects of vaccines: \nevidence and causality. Washington, DC: The National Academies \nPress; 2012.\n\t38.\tAyoola EA, Johnson AO. Hepatitis B vaccine in pregnancy: immunogenicity, \nsafety and transfer of antibodies to infants. Int J Gynaecol Obstet 1987;\u200b\n25:297\u2013301. \n\t39.\tLevy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal \nsafety. Am J Perinatol 1991;8:227\u201332.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_119",
        "document_id": "rr6210",
        "text": "safety. Am J Perinatol 1991;8:227\u201332. \n\t40.\tLeuridan E, Van Damme P. Hepatitis B and the need for a booster dose. \nClin Infect Dis 2011;53:68\u201375. \n\t41.\tMcMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and \nprotection after hepatitis B vaccine: results of a 22-year follow-up study \nand response to a booster dose. J Infect Dis 2009;200:1390\u20136.\n\t42.\tJack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of \nhepatitis B antibody is protective? J Infect Dis 1999;179:489\u201392. \n\t43.\tAlika\u015fifo\u011flu M, Cullu F, Kutlu T, et al. Comparison study of the \nimmunogenicity of different types and dosages of recombinant \nhepatitis B vaccine in healthy neonates. J Trop Pediatr 2001;47:60\u20132.\n\t44.\tGoldfarb J, Baley J, Medendorp SV, et al. Comparative study of the",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_120",
        "document_id": "rr6210",
        "text": "44.\tGoldfarb J, Baley J, Medendorp SV, et al. Comparative study of the \nimmunogenicity and safety of two dosing schedules of Engerix-B \nhepatitis B vaccine in neonates. Pediatr Infect Dis J 1994;13:18\u201321. \n\t45.\tSchillie SF, Murphy TV. Seroprotection after recombinant hepatitis B \nvaccination among newborn infants: a review. Vaccine 2013;31:2506\u201316. \n\t46.\tBouter KP, Diepersloot RJ, Wismans PJ, et al. Humoral immune response \nto a yeast-derived hepatitis B vaccine in patients with type 1 diabetes \nmellitus. Diabet Med 1992;9:66\u20139. \n\t47.\tWeber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity \nas a predictor of poor antibody response to hepatitis B plasma vaccine. \nJAMA 1985;254:3187\u20139. \n\t48.\tWood RC, MacDonald KL, White KE, et al. Risk factors for lack of",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_121",
        "document_id": "rr6210",
        "text": "JAMA 1985;254:3187\u20139. \n\t48.\tWood RC, MacDonald KL, White KE, et al. Risk factors for lack of \ndetectable antibody following hepatitis B vaccination of Minnesota \nhealth care workers. JAMA 1993;270:2935\u20139. \n\t49.\tDentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody \nto hepatitis B and protection from disease among Alaska natives \nimmunized at birth. Pediatr Infect Dis J 2005;24:786\u201392. \n\t50.\tHammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in \nchildren vaccinated with recombinant hepatitis B vaccine beginning at \nbirth: a follow-up study at 15 years. Vaccine 2007;25:6958\u201364. \n\t51.\tMiddleman AB, Baker C, Hu DJ, et al. Duration of immunity from \nhepatitis B vaccine administered soon after birth among 16 to 19 year",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_122",
        "document_id": "rr6210",
        "text": "hepatitis B vaccine administered soon after birth among 16 to 19 year \nold youth in the United States. Presented to the Pediatric Academic \nSocieties, Boston, MA, April 29, 2012.\n\t52.\tPetersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B \nimmunity in low risk children receiving hepatitis B vaccinations from \nbirth. Pediatr Infect Dis J 2004;23:650\u20135. \n\t53.\tSamandari T, Fiore AE, Negus S, et al. Differences in response to a \nhepatitis B vaccine booster dose among Alaskan children and adolescents \nvaccinated during infancy. Pediatrics 2007;120:e373\u201381. \nRecommendations and Reports\n18\t\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\n\t54.\tAdvisory Committee on Immunization Practices. Reilly M. Evidence \nfor cost-effectiveness analysis: non-cost related model inputs. Atlanta,",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_123",
        "document_id": "rr6210",
        "text": "for cost-effectiveness analysis: non-cost related model inputs. Atlanta, \nGeorgia: CDC; 2012. Available at http://www.cdc.gov/vaccines/acip/\nmeetings/downloads/min-archive/min-jun12.pdf. \n\t55.\tFunderburke PL, Spencer L. Hepatitis B immunity in high risk health \ncare workers. Seven years post vaccination. AAOHN J 2000;48:325\u201330.\n\t56.\tMcMahon B, editor. 30 year follow-up after Hepatitis B vaccination in \nadults and children. Technical Viral Hepatitis Prevention Board meeting; \nMilan, Italy; 2011.\n\t57.\tMcMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and \nprotection after hepatitis B vaccination: results of a 15-year follow-up. \nAnn Intern Med 2005;142:333\u201341. \n\t58.\tSpradling PR, Williams RE, Xing J, Soyemi K, Towers J. Serologic testing",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_124",
        "document_id": "rr6210",
        "text": "58.\tSpradling PR, Williams RE, Xing J, Soyemi K, Towers J. Serologic testing \nfor protection against hepatitis B virus infection among students at a \nhealth sciences university in the United States. Infect Control Hosp \nEpidemiol 2012;33:732\u20136. \n\t59.\tStevens CE, Toy PT, Taylor PE, Lee T, Yip HY. Prospects for control of \nhepatitis B virus infection: implications of childhood vaccination and \nlong-term protection. Pediatrics 1992;90:170\u20133.\n\t60.\tTohme RA, Ribner B, Huey MJ, Spradling PR. Hepatitis B vaccination \ncoverage and documented seroprotection among matriculating healthcare \nstudents at an academic institution in the United States. Infect Control \nHosp Epidemiol 2011;32:818\u201321. \n\t61.\tWatson B, West DJ, Chilkatowsky A, Piercy S, Ioli VA. Persistence of",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_125",
        "document_id": "rr6210",
        "text": "61.\tWatson B, West DJ, Chilkatowsky A, Piercy S, Ioli VA. Persistence of \nimmunologic memory for 13 years in recipients of a recombinant \nhepatitis B vaccine. Vaccine 2001;19:3164\u20138. \n\t62.\tWilliams JL, Christensen CJ, McMahon BJ, et al. Evaluation of the \nresponse to a booster dose of hepatitis B vaccine in previously immunized \nhealthcare workers. Vaccine 2001;19:4081\u20135. \n\t63.\tPoovorawan Y, Chongsrisawat V, Theamboonlers A, et al. Evidence of \nprotection against clinical and chronic hepatitis B infection 20 years \nafter infant vaccination in a high endemicity region. J Viral Hepat 2011;\u200b\n18:369\u201375. \n\t64.\tZhu CL, Liu P, Chen T, et al. Presence of immune memory and immunity \nto hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine \n2011;29:7835\u201341.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_126",
        "document_id": "rr6210",
        "text": "to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine \n2011;29:7835\u201341. \n\t65.\tByrd KB, Lu PJ, Murphy TV. Hepatitis B vaccination coverage among health-\ncare personnel in the United States. Public Health Rep 2013;128:498\u2013509.\n\t66.\tCDC. Healthy people topics and objectives index. Available at http://\nwww.healthypeople.gov/2020/topicsobjectives2020/default.aspx.\n\t67.\tCDC. Harriman K. Survey administered to infection preventionists in \nCalifornia healthcare institutions. Atlanta, GA: CDC; 2012.\n\t68.\tClemens R, Sanger R, Kruppenbacher J, et al. Booster immunization of \nlow- and non-responders after a standard three dose hepatitis B vaccine \nschedule\u2013results of a post-marketing surveillance. Vaccine 1997;15:349\u201352.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_127",
        "document_id": "rr6210",
        "text": "schedule\u2013results of a post-marketing surveillance. Vaccine 1997;15:349\u201352. \n\t69.\tCraven DE, Awdeh ZL, Kunches LM, et al. Nonresponsiveness to \nhepatitis B vaccine in health care workers. Results of revaccination and \ngenetic typings. Ann Intern Med 1986;105:356\u201360. \n\t70.\tBertino JS Jr, Tirrell P, Greenberg RN, et al. A comparative trial of standard \nor high-dose S subunit recombinant hepatitis B vaccine versus a vaccine \ncontaining S subunit, pre-S1, and pre-S2 particles for revaccination of \nhealthy adult nonresponders. J Infect Dis 1997;175:678\u201381. \n\t71.\tGoldwater PN. Randomized, comparative trial of 20 micrograms vs \n40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. \nVaccine 1997;15:353\u20136. \n\t72.\tAlter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_128",
        "document_id": "rr6210",
        "text": "Vaccine 1997;15:353\u20136. \n\t72.\tAlter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology \nof hepatitis B in the United States: need for alternative vaccination \nstrategies. JAMA 1990;263:1218\u201322. \n\t73.\tOsterholm MT, Garayalde SM. Clinical viral hepatitis B among \nMinnesota hospital personnel: results of a ten-year statewide survey. \nJAMA 1985;254:3207\u201312. \n\t74.\tTosti ME, editor. Breakthrough HBV infections in vaccinated people: \na ten-year surveillance study in Italy. Technical Viral Hepatitis Prevention \nBoard meeting. Milan, Italy; 2011.\n\t75.\tCDC. Assessment of Hepatitis B vaccination history among healthcare \npersonnel with acute Hepatitis B. CDC Surveillance Project; 2012.\n\t76.\tCDC. Immunization Information Systems. Available at http://www.cdc.gov/",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_129",
        "document_id": "rr6210",
        "text": "76.\tCDC. Immunization Information Systems. Available at http://www.cdc.gov/\nvaccines/programs/iis/index.html.\n\t77.\tCDC. Immunization Information Systems. Personal communication, \nGary Urquhart; 2012.\n\t78.\tShi Z, Li X, Ma L, Yang Y. Hepatitis B immunoglobulin injection in \npregnancy to interrupt hepatitis B virus mother-to-child transmission-a \nmeta-analysis. Int J Infect Dis 2010;14:e622\u201334. \n\t79.\tBeasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally \ntransmitted hepatitis B virus infections with hepatitis B virus infections \nwith hepatitis B immune globulin and hepatitis B vaccine. Lancet \n1983;2:1099\u2013102. \n\t80.\tStevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission \nin the United States: prevention by passive-active immunization. JAMA \n1985;253:1740\u20135.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_130",
        "document_id": "rr6210",
        "text": "in the United States: prevention by passive-active immunization. JAMA \n1985;253:1740\u20135. \n\t81.\tBeasley RP, Hwang LY, Stevens CE, et al. Efficacy of hepatitis B immune \nglobulin for prevention of perinatal transmission of the hepatitis B virus \ncarrier state: final report of a randomized double-blind, placebo-\ncontrolled trial. Hepatology 1983;3:135\u201341. \n\t82.\tGrady GF, Lee VA, Prince AM, et al. Hepatitis B immune globulin for \naccidental exposures among medical personnel: final report of a multicenter \ncontrolled trial. J Infect Dis 1978;138:625\u201338. \n\t83.\tPrince AM, Szmuness W, Mann MK, et al. Hepatitis B immune globulin: \nfinal report of a controlled, multicenter trial of efficacy in prevention of \ndialysis-associated hepatitis. J Infect Dis 1978;137:131\u201344.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_131",
        "document_id": "rr6210",
        "text": "dialysis-associated hepatitis. J Infect Dis 1978;137:131\u201344. \n\t84.\tPrince AM, Szmuness W, Mann MK, et al. Hepatitis B \u201cimmune\u201d \nglobulin: effectiveness in prevention of dialysis-associated hepatitis. \nN Engl J Med 1975;293:1063\u20137. \n\t85.\tSeeff LB, Wright EC, Zimmerman HJ, et al. Type B hepatitis after needle-\nstick exposure: prevention with hepatitis B immune globulin. Final report \nof the Veterans Administration Cooperative Study. Ann Intern Med \n1978;88:285\u201393. \n\t86.\tSeeff LB, Zimmerman HJ, Wright EC, et al. A randomized, double \nblind controlled trial of the efficacy of immune serum globulin for the \nprevention of post-transfusion hepatitis: a Veterans Administration \ncooperative study. Gastroenterology 1977;72:111\u201321.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_132",
        "document_id": "rr6210",
        "text": "cooperative study. Gastroenterology 1977;72:111\u201321.\n\t87.\tKrugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain) \nprevention with specific hepatitis B immune serum globulin. JAMA \n1971;218:1665\u201370. \n\t88.\tWauters JP, Leski M. Delayed hepatitis after treatment with hepatitis B \nimmune serum globulin. BMJ 1976;2:19\u201320. \n\t89.\tZhou F, Euler GL, McPhee SJ, et al. Economic analysis of promotion \nof hepatitis B vaccinations among Vietnamese-American children and \nadolescents in Houston and Dallas. Pediatrics 2003;111:1289\u201396. \n\t90.\tCDC. Guideline for infection control in health care personnel, 1998. \nAvailable at http://www.cdc.gov/hicpac/pdf/infectcontrol98.pdf.\n\t91.\tBolyard EA, Tablan OC, Williams WW, et al. Guideline for infection",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_133",
        "document_id": "rr6210",
        "text": "91.\tBolyard EA, Tablan OC, Williams WW, et al. Guideline for infection \ncontrol in healthcare personnel, 1998: Hospital Infection Control \nPractices Advisory Committee. Infect Control Hosp Epidemiol \n1998;19:407\u201363. \n\t92.\tEnfield KB, Sharapov U, Hall KK, et al. Transmission of hepatitis B \nvirus from an orthopedic surgeon with a high viral load. Clin Infect Dis \n2013;56:218\u201324. \nRecommendations and Reports\nMMWR\u2002 /\u2002 December 20, 2013\u2002 /\u2002 Vol. 62\u2002 /\u2002 No. 10\t\n19\nExpert Panel Members\nDouglas Campos-Outcalt, MD, University of Arizona College of Medicine, Phoenix, Arizona; Alexis Elward, MD, Washington University School of \nMedicine, St Louis, Missouri; Kathleen Harriman, PhD, California Department of Public Health, Richmond, California; Samuel Katz, MD, Duke University,",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_134",
        "document_id": "rr6210",
        "text": "Durham, North Carolina; Harry Keyserling, MD, Emory University School of Medicine, Atlanta, Georgia; Thomas Koinis, MD, Duke University, Oxford, \nNorth Carolina; Susan Lett, MD, Massachusetts Department of Public Health, Boston, Massachusetts; Brian McMahon, MD, Alaska Native Tribal Health \nConsortium, Anchorage, Alaska; Amy Middleman, MD, Baylor College of Medicine, Houston, Texas; David A. Nace, MD, American Medical Directors \nAssociation, Columbia, Maryland; Mark Sawyer, MD, University of California at San Diego, California; Brenna Simons, PhD, Alaska Native Tribal Health \nConsortium, Anchorage, Alaska; Jonathan Temte, MD, PhD, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; James",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_135",
        "document_id": "rr6210",
        "text": "Turner, MD, University of Virginia School of Medicine, Charlottesville, Virginia; David Weber, MD, Society for Healthcare Epidemiology of America, \nUniversity of North Carolina, Chapel Hill, North Carolina; Marion Major, PhD, Food and Drug Administration, Bethesda, Maryland; Marie A. de Perio, \nMD, National Institute for Occupational Safety and Health; Geoff Beckett, PA-C, Kathy Byrd, MD, Scott Holmberg, MD, Trudy V. Murphy, MD, Sarah \nSchillie, MD, Philip Spradling, MD, Eyasu Teshale, MD, Fujie Xu, MD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention; Erin \nKennedy, DVM, National Center for Immunization and Respiratory Diseases; David Kuhar, MD, Cindy Weinbaum, MD, National Center for Emerging \nand Zoonotic Infectious Diseases.\nDisclosure of Competing Interests",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_136",
        "document_id": "rr6210",
        "text": "and Zoonotic Infectious Diseases.\nDisclosure of Competing Interests\nThe developers of these guidelines wish to disclose that they have no financial interests or other relationships with the manufacturers of commercial products \nor suppliers of commercial services related to vaccines including any related to hepatitis B vaccines, with the following exceptions: David Weber, MD, wishes \nto disclose that he served as a consultant and on a speakers\u2019 bureau, whether paid or unpaid (e.g., travel related reimbursement, honoraria), for the following \nvaccine manufacturers: Merck, Sanofi, and Pfizer pharmaceutical companies. Amy B. Middleman, MD, also wishes to disclose that she received grant funding \nfrom the following pharmaceutical companies:  MedImmune, Sanofi, and Merck.\n\u2003\n\u2003\n\u2003\nISSN: 1057-5987",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_137",
        "document_id": "rr6210",
        "text": "from the following pharmaceutical companies:  MedImmune, Sanofi, and Merck.\n\u2003\n\u2003\n\u2003\nISSN: 1057-5987\nThe Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free \nof charge in electronic format. To receive an electronic copy each week, visit MMWR\u2019s free subscription page at http://www.cdc.gov/mmwr/mmwrsubscribe.\nhtml. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; \ntelephone 202-512-1800.\nAddress all inquiries about the MMWR Series, including material to be considered for publication, to Editor, MMWR Series, Mailstop E-90, CDC, 1600 \nClifton Rd., N.E., Atlanta, GA 30333 or to mmwrq@cdc.gov.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    },
    {
        "chunk_id": "rr6210_chunk_138",
        "document_id": "rr6210",
        "text": "Clifton Rd., N.E., Atlanta, GA 30333 or to mmwrq@cdc.gov. \nAll material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.\nUse of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.\nReferences to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations \nor their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses \nlisted in MMWR were current as of the date of publication.",
        "metadata": {
            "year": "unknown",
            "disease_type": "general_guideline",
            "source": "clinical_guideline"
        }
    }
]